Mechanisms of dengue virus neutralization by antibody by Wahala, Wahala Mudiyanselage Padmasriri Bandara
  
 
 
 
 
MECHANISMS OF DENGUE VIRUS NEUTRALIZATION BY ANTIBODY 
 
 
 
 
Wahala Mudiyanselage Padmasriri Bandara Wahala 
 
 
 
 
A dissertation submitted to the faculty of the University of North Carolina at 
Chapel Hill in partial fulfillment of the requirements for the degree of  
Doctor of Philosophy in the Department of Microbiology and Immunology 
 
 
 
 
 
Chapel Hill 
2009 
 
 
 
 
 
 
Approved by: 
Aravinda de Silva , MPH, PhD. 
Robert E Johnston, PhD. 
Edward J Collins, PhD. 
Raymond J Pickles, PhD. 
Laura J White, PhD. 
                                                                                                         Ronald  I  Swanstrom, PhD.  
 
 ii
 
 
 
 
 
ABSTRCT 
 
WAHALA MUDIYANSELAGE PADAMASIRI BANDARA WAHALA:  
Mechanisms of dengue virus neutralization by antibody 
(under the direction of Aravinda de Silva) 
 
 
Dengue virus (DENV), the causative agent of dengue, is a group of viruses consisting 
of four different serotypes designated DENV1-4.  Each serotype is further divided into 
different genotypes. Primary DENV infection induces a life-long type-specific immune 
response against the homologous DENV serotype.  It is widely assumed that all the strains of 
a DENV serotype are equally neutralized by type-specific antibodies irrespective of the 
genetic variability within the serotype.  Studies with mouse monoclonal antibodies (mAb) 
have demonstrated that serotype-specific neutralization of DENV is mainly mediated by 
antibody binding to epitopes on domain III of the viral Envelope protein (EDIII).  
Although DENV3 has spread worldwide, neutralization mechanisms of DENV3 is 
poorly studied. Results of my studies with mouse mAbs demonstrate that type-specific 
neutralization of DENV3 was confined to EDIII lateral ridge as reported for other 
flaviviruses.  I further demonstrated that DENV3 Envelope (E) protein sequences were 
variable between different genotypes of DENV3.  Variable positions were located on or near 
the known antibody epitopes on E protein, and natural amino acid variations of DENV3 E 
protein led to complete or partial escape from antibody neutralization.  These results suggest 
that natural intra-serotype variation should be considered when characterizing natural and 
vaccine induced immunity. 
 iii
The specificity and functionality of the human antibody response to DENV is poorly 
characterized.   It is unknown if humans also develop antibodies to EDIII epitopes 
recognized by mouse mAbs.  Using a panel of sera from people exposed to DENV, I 
demonstrate that people develop low levels of type-specific EDIII reactive antibodies after 
primary infection and low levels of serotype cross reactive EDIII antibodies after secondary 
infection.  I further demonstrated that these low levels of EDIII reactive antibodies only 
make a minor contribution to the total neutralization potency of human immune sera.  I 
conclude that the EDIII epitopes identified using mouse reagents, which have been the focus 
of much recent work, are not the primary target of human antibodies that neutralize DENV.  I 
believe these results will stimulate investigators to study previously neglected regions of the 
DENV envelope to identify functionally important epitopes engaged by human antibodies.  
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1.1 Introduction: 
Antibodies are a main line of defense against dengue and other flaviviruses.   
However, the antibody response against dengue virus (DENV) can either be pathogenic or 
protective [1].  Studies conducted with mouse monoclonal antibodies ( mAb) have 
demonstrated that strongly neutralizing antibodies bind to domain III of the envelope protein 
(EDIII) [2].  Very little is known about how human antibodies neutralize DENV.  Moreover, 
although it is widely assumed that a neutralizing antibody against one DENV strain is 
effective against all strains within a DENV serotype, there is little experimental evidence to 
support this assumption.  This thesis describes studies to characterize the binding and 
functionality of human polyclonal and mouse mAbs to DENVs.  Using DENV type 3 as a 
model, studies were conducted to determine if strain variation has an impact on DENV-
antibody interactions. 
The following sections briefly introduce dengue (DEN) disease, the responsible 
viruses, the host immune response, general mechanisms of virus neutralization by antibody 
and, more specifically, current state of knowledge about antibody binding and neutralization 
of flaviviruses, including dengue.  Following this background, I will introduce the main 
questions to be addressed in this thesis. 
 
1.2 Dengue disease, dengue virus, its transmission and global distribution: 
 Dengue is a re-emerging mosquito-borne viral disease of the tropics and subtropics 
caused by a group of viruses designated DENVs.  Although, the disease was first described 
in 1779, DENV was first isolated from infected patients in the mid 19th century [3-5].  
DENVs are transmitted by Aedes mosquitoes.  Two distinct DENV transmission cycles 
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namely sylvatic cycle and endemic cycle occur.  In the sylvatic or enzootic cycle, DENVs are 
transmitted between non-human primates and arboreal Aedes spp.  However, in the urban or 
endemic cycle, DENVs, which are thought to have evolved from sylvatic DENVs over two 
hundred years ago, are transmitted between humans and Aedes aegypti and Aedes albopictus 
mosquitoes [6].  The human is the primary host in the urban cycle and human infection is 
essential for the survival of the virus in the urban setting [7].  It is estimated  that 50 million 
dengue infections occur annually in about 100 countries worldwide and approximately 
500,000 (1%) require hospitalizations with a death rate of ~ 2.5 % (12,000 of 500,000) [8].  
Currently no antiviral drugs or vaccines are available to control the disease. 
 
1.3 Classification and the structure of DENV: 
 DENV is a member of the genus Flavivirus in the family Flaviviridae.  The genus 
flavivirus is further divided into different groups or sero-complexes which include many 
pathogenic viruses that cause a variety of diseases ranging from fever to encephalitis and 
hemorrhagic fevers.  Some of the flaviviruses of global heath concern are DENV, Japanese 
encephalitis virus (JEV), West Nile virus (WNV), yellow fever virus (YFV), Murray Valley 
encephalitis virus (MVEV), St. Louis encephalitis virus (SLEV), and tick-borne encephalitis 
virus (TBEV) [9].  The DENV group consists of four closely related, but distinct virus 
species which have traditionally been called serotypes, namely DENV serotype 1 through 
DENV serotype 4 [10]. Each DENV serotype can be further divided into different genotypes 
[11]. For instance, DENV serotype 3 consists of four different genotypes namely DENV3-
genotype I through DENV3-genotype IV [12].  
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 DENV is an enveloped virus with a diameter of approximately 50 nm [13].  The 
genome of DENV, which is approximately 10.7 kb in size, is a positive sense single stranded 
RNA with a single open reading frame [9].  Furthermore, the genome is flanked by 
untranslated regions (UTR) at both the 3’ and the 5’ ends, which are important for initiation 
and regulation of protein translation, genome replication and virus assembly (figure 1.1) 
[9,14,15]. The genome encodes three structural proteins (capsid, envelope, pre-
membrane/membrane) and 7 non-structural (NS) proteins (NS1, NS2A, NS2B, NS3, NS4A, 
NS4B, NS5) which are translated as a polyprotein and co- and post-translationally cleaved by 
signal peptidases, the viral serine protease, and additional cellular proteases (figure 1.1) [9].  
The nucleocapsid, which is made of multiple copies of capsid (C) protein that associates with 
the ssRNA genome, is surrounded by an envelope [9].  The envelope of the mature virion, 
which arranges into an icosahedral symmetry, is primarily made of two structural proteins; 
envelope glycoprotein (E protein) and the membrane (M) protein (figure 1.1 and 1.2) [9].  Of 
the 7 non-structural (NS) proteins, NS5 is the RNA-dependent RNA polymerase (RdRp) and 
methyltransferase whereas NS3 functions as serine protease, helicase and nucleoside 
triphosphatase [9,14].  In addition, NS2B is required as a cofactor for the NS3 serine 
protease. The known functions of NS proteins are summarized in the figure1.1, although the 
functions of some of the NS proteins have yet to be determined. 
 
1.4 Replication and life cycle of DENV: 
The primary targets of the DENV are the cells of mononuclear phagocyte lineage 
including monocytes, macrophages, and dendritic cells (DCs).  However, B cells, T cells, 
endothelial cells, hepatocytes, and neuronal cells, are also permissive to DENV [14].  
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Although, the cellular receptor, which mediates the entry of DENV, is not known, putative 
attachment receptors such as dendritic cell-specific intercellular adhesion molecule-3-
grabbing non-integrin  (DC-SIGN or CD209), mannose Receptor (MR), heparan sulfate 
(HS), heat shock proteins (HSP) 70 and 90, and CD14 linked molecule have been studied to 
date [9,14,16].  The entry of DENV to permissive cells occurs through  receptor-mediated 
endocytosis [9].  Conformational rearrangement of the E protein, which occurs in the acidic 
endosome, induces the fusion process, which in turn releases the nucleocapsid into the 
cytoplasm of the cells.  Translation and replication of DENV occurs in association with 
intracellular membranous structures [9].  The new immature DENV particles, which bud into 
the lumen of the ER, consist of trimeric spikes of pre-membrane (prM) and E protein 
heterodimers (figure 1.3)[9].  The prM protein is cleaved by furin and the E protein is 
rearranged into dimers in an icosahedral symmetry when the immature DENV particles 
egress through the transgolgi network.  Consequently, the mature DENV is released by 
exocytosis (figure 1.3) [9].  However, cell culture-derived DENV, as well as other 
flaviviruses, is a mixture of mature and immature virus particles, and some immature virus 
particles consist of partially mature and immature E protein on the virion envelope [17].  
 
1.5 Dengue: the disease and pathogenesis. 
 All four serotypes of DENV often cocirculate in DEN endemic areas [8]. Therefore, 
heterologous, sequential secondary DENV infections are common [18].  The spectrum of 
disease in both primary and secondary infection is quite diverse ranging from asymptomatic 
or mild undifferentiated fever, to classic dengue fever (DF), to more severe disease such as 
dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS) [18-20].  In children 
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most of the DENV infections remain asymptomatic and only 3-5% of infected children 
develop DHF/DSS [18].  The pathogenesis of DHF/DSS is not well understood mainly due to 
the lack of suitable animal models [21].  Nevertheless, secondary DENV infection is a major 
risk factor for developing DHF/DSS [1].  Antibody-dependent enhancement (ADE) model 
has been proposed to explain the increased risk of DHF/DSS in secondary DENV infection 
[1,22].  According to the ADE model, cross-reactive, weakly neutralizing or non-neutralizing 
antibodies from a previous DENV infection interact with a heterologous DENV strain 
without neutralizing it, thus facilitating the uptake of the virus by Fcγ receptor-bearing cells 
such as monocytes/macrophages and increasing the viral burden in the host [1].  Although 
ADE induces caspase-dependent apoptosis and the production of inflammatory cytokines and 
chemokines that modulate vascular permeability, the molecular mechanism underpinning 
ADE-driven DHF/DSS is not yet well characterized [23].  In addition, a secondary infection 
is also believed to induce the expansion of low affinity, cross-reactive memory T cells, which 
are generated upon the primary DENV infection.  These cross-reactive memory T cells, 
which are incapable of eliminating the heterologous DENV virus, induce over production of 
pro-inflammatory cytokines such as IFNγ and TNFα that increase vascular permeability 
leading to DHF/DSS [24]. 
  In addition, some DENV antibodies, that cross-react with endothelial cells, blood 
clotting factors and platelets, are additional mediators believed to induce DHF/DSS [25,26].  
Host genetic factors such as human leukocyte antigen (HLA) type, polymorphism in the 
genes of TNFα, CD209, Gluose 6 phosphate dehydrogenase (G6PD), FCγ receptor, receptor 
for vitamin D, as well as  age, race and nutrient status of the host are also important factors 
that can contribute to DHF/DSS [27]. In addition, some DENV strains are more virulent than 
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the others and may contribute to severe disease [11].  The virulence of such strains has been 
attributed to the prM, E, NS4b, NS5 proteins and 3’and 5’ UTR of the DENV genome [28]. 
 
1.6 Protective host immune response against DENV infection: 
 The innate immune response, especially IFNα/β and IFNγ, likely protects from 
DENV infection [29].  However, it has been demonstrated that DENV (and other 
flaviviruses), use a variety of mechanisms to evade the IFN-mediated antiviral response 
[30,31].  In addition, DENV-specific CD4 and CD8 cells are cytolytic against DENV- 
infected cells [32,33].  In contrast, cross-reactive T cells are believed to be pathogenic 
particularly in heterologous secondary DENV infection [32].  
  Humoral immunity is a key factor in controlling DENV infection in the host. Studies 
conducted with humans and experimental animals have demonstrated that passively 
transferred polyclonal sera and monoclonal Abs protect from DENV infection [3,34,35]. In a 
typical natural DENV infection, viremia peaks around day 4 after the onset of the disease and 
declines when the initial Immunoglobulin M (IgM) antibody response develops.  The IgG 
response appears 6-7 days after the onset of fever, and although IgM is detectable in patient 
sera for only a few months post-infection, IgG titers can remain in the patients’ sera 
throughout their lifetime [36].  After a primary infection with one serotype of DENV, a short 
period of broad cross protection against multiple serotypes is observed.  People subsequently 
develop a serotype-specific, long-term neutralizing antibody response against the serotype 
responsible for the primary infection only [3,36].  Primary DENV infection also elicits cross 
reactive, weakly neutralizing and non-neutralizing antibodies.  Instead of neutralizing, these 
antibodies may enhance secondary infection with a heterologous DENV [1]. 
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Many studies have focused on understanding the mechanisms of neutralization of 
flaviviruses using monoclonal antibodies. Although, most of these studies identified 
neutralizing mAb binding epitopes and their mechanisms, very little is known about the 
neutralizing antibody response and the mechanisms of neutralization of virus by human 
immune polyclonal sera.  
 
1.7 Mechanisms and theories of virus neutralization by antibody 
The humoral immune response plays a major role in protecting from flavivirus 
infection including DENV.  Therefore, understanding the mechanism of virus neutralization 
by antibodies is pivotal toward developing better vaccine candidates and understanding the 
characteristics of different epitopes of the enhancing Abs that induce ADE.  The mechanisms 
of virus neutralization are usually studied in vitro by using monoclonal antibodies (mAb). 
Such studies have shown that viral neutralization can be accomplished at different stages of 
the virus life cycle.  In the following section, the known stages of the virus life cycle targeted 
by neutralizing antibodies are described in detail. 
 
Aggregation and disintegration of virus particles 
The simplest mechanism of neutralization occurs when Abs neutralize viruses by 
cross-linking and aggregating viral particles.  The aggregation of viral particles by 
neutralizing antibodies has been studied in detail using poliovirus with mAb 35-1f4 [37,38].  
These studies demonstrated that while the virions in the aggregates were still infectious, 
aggregation reduced the infectivity of the virus proportionately to the number of virions in an 
aggregate.  When the aggregates were disintegrated, individual virions regained infectivity 
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[37-39].  However, it was further demonstrated that aggregation only occurred when the 
antibodies interacted with the viral particle monovalaently, allowing both Fab arms to bind to 
different virions.  However, aggregation was dependent upon a concentration phenomenon, 
in that aggregation did not occur in the presence of high IgG concentration when epitopes 
were saturated [38].  
Neutralization of some viruses can be obtained by destabilizing the virus particle.  
Poliovirus and foot and mouth disease virus (FMDV) are disintegrated and become 
noninfectious after binding to certain antibodies.  As mentioned earlier, poliovirus can be 
reversibly neutralized by the mAb 35-1f4 by aggregating the virus particles under normal 
physiological conditions.  However, under different physiological conditions, the same 
antibody neutralizes the poliovirus in vitro by dismantling the virus structure.  At 
physiological ionic conditions and 39C, or low ionic conditions and 37C, mAb 35-1f4 
changes the structure of poliovirus irreversibly and neutralizes by releasing RNA 
prematurely from the virion [40,41].  A similar destruction of poliovirus at 39C at 
physiological ionic strength occurs with polyclonal immune sera as well [41].  Neutralization 
of  FMDV by mAb 4C9 is also mediated by structural changes in the capsid protein, which 
induces the release of viral RNA.  However, unlike poliovirus, structural changes of FMDV 
happen under normal physiological conditions and temperatures [42].  Although the exact 
mechanisms of such conformational changes are not known, it is likely that Ab binding 
mimics the virus-receptor attachment and thus induces the conformational changes leading to 
premature uncoating of the virus 
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Block receptor attachment 
Attachment of a virus to its cellular receptor or group of receptors is essential for 
successful infection.  Receptor interactions may be cell-type specific for one virus although 
the same virus may use different receptors on different cell types.  Moreover, some viruses 
use more than one receptor.  The primary receptor is used as the attachment factor which 
brings the virus closer to the co- or ancillary receptor, whose attachment induces the fusion 
or internalization and fusion of the virus.  It has been shown that antibody blocking the 
receptor attachment of virus is a major mechanism of virus neutralization [43].  In this 
mechanism of neutralization, antibodies inhibit the receptor - virus interaction by binding to 
the specific receptor binding domain of the viral protein and thus occupying the interacting 
sites of the receptors.  Neutralization of DENV in Vero cells, and human immunodeficiency 
virus-type1 (HIV-I) in T cell lines is mediated in this fashion [44,45].  Furthermore, 
neutralization of HIV-1 by human monoclonal antibody F105 occurs by inhibiting the 
attachment of the cellular receptor, CD4, to the viral glycoprotein 120 (gp120).  The epitope 
that mAb F105 binds is located on the V3 loop of gp120 and partially overlaps with the CD4 
binding site [46,47].  However, receptor attachment can also be blocked by an Ab without 
directly engaging the receptor binding motif but by occluding the binding area.  A classic 
example for such a mechanism of neutralization occurs in neutralization of human rhinovirus 
14 (HRV-14) by mAb 17IA [48].  The attachment domain for the intercellular adhesion 
molecule-I (ICAM-I) cellular receptor is located in the canyon of the capsid of HRV14 and 
inaccessible to mAb17IA.  The structural and mutational studies conducted by Smith et al 
have revealed that Fab fragment of mAb 17IA binds to an immunogenic site over the canyon 
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area [48]. Thus the antibody binds bivalently across the two fold axis of the protein masking 
the canyon and subsequently blocking receptor attachment [48]. 
The conformational rearrangement of the viral protein, which exposes the co-receptor 
binding sites upon binding to the primary receptor, also plays a role in virus neutralization by 
Abs that target the co-receptor attachment. [49]. Viruses such as HIV-1, herpes simplex virus 
(HSV), and FMDV use a primary receptor to bind to the cell and co-receptors for completing 
fusion with cellular membrane.  Once the primary receptor, CD4, binds to gp120 of HIV-1, 
co-receptor binding sites on gp120 are exposed.  Antibodies 17b and 48d bind to these co-
receptor binding sites, which are termed as CD4-induced gp120 epitopes [49].  These 
antibodies can neutralize HIV-1 only after the virus binds to its primary CD4 receptor.  In 
addition, some HIV-1- neutralizing antibodies can bind to the gp120-CD4 binding site as 
well as the gp120-co-receptor binding sites [49].   
 
Neutralization of virus at a post attachment step: 
Another important step in the viral life cycle that is often targeted by neutralizing Ab 
(nAb) is the entry of the virus into the cells.  Since this step is preceded by the attachment of 
the virus to the receptor and/or co-receptor, the step is frequently designated post-attachment 
neutralization (PAN).  PAN is usually differentiated from standard neutralization (STAN) in 
vitro by investigating the neutralization potential of an antibody after the virus has attached 
to the cells.  PAN has been documented with many viruses including HIV-1, influenza A 
virus, poliovirus, respiratory syncytial virus, Venezuelan equine encephalitis virus (VEEV), 
rabies virus, enterovirus 71 , rotavirus , Newcastle disease virus, transmissible gastroenteritis 
virus, vesicular stomatitis virus, adenovirus, human cytomegalovirus, African swine fever 
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virus and various flaviviruses. (cited in [50,51]).  One well studied mechanism of PAN is 
inhibition of the viral-cell membrane fusion.  Influenza, HIV-1 and flavivirus fusion proteins 
have been well studied, and these proteins are present on the native virus particle in a 
metastable pre-fusion stage [52].  The pre-fusion proteins undergo conformational 
rearrangements, which are induced by acidic pH (for influenza and flavivirus) or attachment 
to the primary receptor and co-receptor (for HIV-1), to become fusogenic [52].  Therefore, 
binding of an antibody to the envelope protein may block the fusion by interfering with 
attachment of the fusion receptor, by obstructing the juxtaposition of the cellular membrane 
and viral membrane, or by stabilizing the viral fusion protein in the metastable pre-fusion 
stage.  As mentioned earlier, mAb 17b blocks the binding of co-receptor to gp120 of HIV 
and consequently blocks the fusion of HIV particles to the T cell membrane.  Monoclonal Ab 
E16 of WNV and human mAb CR6261 of influenza virus, which recognize epitopes on the E 
protein  and the hemagglutinin (HA) protein respectively,  block the conformational 
rearrangement of the protein thus impeding  membrane fusion [51,53,54].  Moreover, 
hepatitis C virus (HCV) is neutralized by mAb as well as human IgG purified from HCV 
immune sera by blocking  viral fusion with the cell membrane [55]. 
Even though inhibition of receptor binding and fusion are the main attachment and 
entry steps targeted by many antibodies that neutralize viruses, some antibodies inhibit post- 
entry events to neutralize viruses.  It has been proposed that some Abs that bind to the CD4 
receptor inhibit the reverse transcription of HIV-1 thereby preventing viral propagation [56].  
Similar mechanisms have been reported with influenza virus neutralization, as well [57,58].  
In addition, inhibition of virus budding has also been described as another mechanism used 
by Abs to neutralize viruses.  For instance, the mAb 14C2 has been shown to bind to the M2 
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protein on the surface of influenza virus-infected cells, restricting the release of the virus 
[59]. 
  
1.8 Models of Virus neutralization.  
Irrespective of the replicative stage of the virus life cycle targeted by antibodies, 
several models have been proposed to describe the possible mechanisms whereby antibodies 
neutralize viruses.  All models proposed to date are based on the results of in vitro 
neutralization assays conducted using monoclonal antibodies.  The rule of thumb for these 
neutralization  assays is that the Abs need to be in molar excess over the antigen (Ag) used 
and therefore the amount of antigen-bound Abs is negligible compared to the amount of  free 
Abs in the solution throughout the assay [60,61].  
The most discussed physical aspects of neutralization are kinetics of binding and 
molarity of antibody which have been used to describe different models of the neutralization.  
Studies conducted by Dulbecco et al, showed a linear relationship between the rate of 
neutralization and the concentration of an antibody, and these authors proposed that binding 
of a single antibody molecule to one virion particle can successfully neutralize the virus [62].  
This model is widely known as “single-hit phenomenon” or the “single-hit model”, and it 
obeys the rule of first order kinetics.  However, the single-hit phenomenon has proven to be 
of the “pseudo first order kinetics” since the Abs were in molar excess in the neutralization 
reaction, and therefore this model is largely refuted today [60,63].  
On the other hand, “multi-hit phenomenon” which describes the requirement of more 
than one Ab molecule to neutralize a virus particle, is widely accepted today [61,64].  
Neutralization of a virus by multi-hit phenomenon is mediated by multiple Ab molecules that 
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bind and occupy the epitopes of surface proteins (SUs) on the virion particle [64].  The multi- 
hit model is widely known as the occupancy model of virus neutralization [61]. Furthermore, 
this model is strengthened by recent work conducted with HIV and WNV [65-68]. The 
molecularity of neutralization, which is the number of hits required per virion or the 
stoichiometry, can be calculated if the number of available epitopes on the virion particle for 
the particular Ab is known. However, the experiments need to be carefully designed in such a 
way that neutralization and binding of the Ab are measured under the same experimental 
conditions [60,69]. In addition, the following assumptions are necessary to satisfy the 
biological requirements of this model: 1) The neutralizing Abs bind to infectious and non- 
infectious particles equally well, and 2) each virus particle contains the same number of 
epitopes [60].  The binding of antibody can also be expressed as the relative occupancy 
which is the percentage of Ab-bound epitopes compared to the total number of available or 
exposed epitopes on the SUs.  It is proposed that a minimal number of free SUs on the virion 
is required to achieve a successful infection [60,64].  Neutralization starts at a threshold of 
occupancy whereby antibodies occupy the SUs in such a way as to maintain the number of 
unoccupied SUs below minimum number of SUs required for the infectivity [60,64]. 
According to the assumption of the occupancy model, it is obvious that the stoichiometry and 
the relative occupancy of antibodies on a virion particle depends on the density of SUs, the 
spacing of the epitopes, mobility of the SUs, and accessibility of the epitope with regard to 
the properties of the SUs [64].  In addition, affinity and isotype of the antibody are important 
properties of an antibody, which affect the relative occupancy [69,70].  
Nonetheless, the “critical binding site concept” (CBS concept) has also been proposed 
by Dimmock to explain the mechanism of virus neutralization [71].  According to this 
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concept, certain binding sites are involved in neutralization and therefore simply coating or 
occupying many SUs of the virion is not sufficient to neutralize the virus if the critical sites 
are not occupied by the antibodies.  According to the CBS concept, the single-hit model is 
described such that all the available epitopes are critical sites, and therefore binding of a 
single Ab molecule to any of these sites can induce structural changes and inhibit viral 
replication.  The CBS concept can also be used to explain the multi-hit phenomenon, as well. 
Even though antibodies occupy more than one SU, not all are considered as critical sites for 
neutralization.  However, the evidence from many biochemical and structural experiments 
with different viruses strongly supports the occupancy model [65-68]. 
 
1.9 Neutralization of  Flaviviruses by antibodies 
The envelope (E) and M proteins are flavivirus structural proteins found on the 
surface of mature flavivius particles.  E protein is the major envelope protein (~ 55 kDa) that 
mediates receptor attachment and membrane fusion [9].  Most neutralizing monoclonal 
antibodies (nmAb) against flaviviruses described to date recognize epitopes on the E protein 
[72].  However, some nmAb have been reported to bind to epitopes on the prM/M protein of 
the flavivirus, although such antibodies are not common [72-74].  In addition, anti-NS1 
antibodies are important in protection as well as in disease pathogenicity, even though NS1 
protein is not surface exposed [75-80].  Interestingly, NS1 protein has been detected on the 
surface of infected cells, and anti-NS1 antibodies have been shown to be cytolytic in some 
cases [76]. Nevertheless, E protein is considered as the major immunodominant protein of 
the flaviviruses since most neutralizing antibodies studied so far are E protein reactive [72]. 
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Structure of the E protein:  
The crystal structures of E protein of TBE, DENV and WNV have been resolved 
recently, and these structures have advanced our understanding of the involvement of E 
protein in the life cycle of flaviviruses and how antibodies against this protein lead to viral 
neutralization [81-84].  In addition, the crystal structure of the post-fusion conformation of E 
protein has also been resolved [85,86].  Cryo-electron density mapping of mature and 
immature virion particles and the crystal structure of E protein have enabled researchers to 
model the E protein superstructure arrangement on the surface of mature and immature virion 
particles [82,87,88]. One hundred and eighty E protein monomers are arranged into dimers in 
an antiparallel orientation, whereby the dimers lay flat on the surface of the virion to form a 
T=3 pseudo icosahedral symmetry in the mature virion (figure 1.2) [13].  Each monomer of E 
protein is about 495 amino acids (AA) in length, and is anchored to the viral lipid membrane 
by two transmembrane (TM) helices (figure 1.4) [81-84,89].  The ectodomain of the E 
protein, which lies flat on the surface of the virion, is connected to the TM domain by a stem 
region that contains two amphipathic helices.  The amphipathic helices of the stem region 
also lie flat on the viral membrane but are partially buried in the outer leaflet of the lipid 
bilayer (figure 1.4) [89].  The helices in the stem region participate in the conformational 
change of E protein during the fusion process.  The M protein is also comprised of a partially 
buried amphipathic helix and two trans-membrane helices which are closely associated with 
TM helices of the E protein.  These helices serve to stabilize the E protein in mature virion 
particles, as well as the E-prM heterodimers in immature virions [89].  
The flavivirus E protein, which is categorized as a class II fusion protein, differs from 
the class I fusion protein of HIV-1 and influenza virus in its structural arrangement [52].  
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Class I fusion proteins are arranged perpendicular to the virion surface where they are lightly 
pack in the particle, whereas class II fusion proteins are arranged in parallel as dimers that 
pack very tightly in the virion [52].  Structural studies identified three different domains in 
the flavivirus E protein monomer, and these are designated domain I (EDI), domain II (EDII) 
and domain III(EDIII) (figure 1.4)[81,90].  Twelve highly conserved cysteine residues 
stabilize the structure of the E protein through six disulfide bonds, and therefore all flavivirus 
E proteins fold into a similar 3 domain structure [81,90].  All three domains of the E protein 
consist primarily of β strands except two small α helices in the EDII compared to class I 
fusion proteins which are mainly made of α helices.  EDII is the dimerization domain and 
therefore E monomers are not contacted through the entire E monomer to make an E dimer 
[81,90].  Furthermore, EDII contains a hydrophobic fusion peptide at its distal end, which is 
buried at the dimer interface due to the contact of EDIII from a paired E monomer.[81,91]. 
EDI lies in the middle of the monomer connecting both EDII and EDIII through flexible 
hinges.  EDIII, which is connected to EDI by a stretch of 15 amino acids, is an 
immunoglobulin (Ig) like domain and contains a putative receptor binding domain (figure 
1.5)[92].  It is important to note that the β barrel of EDIII is orientated perpendicular to the 
lipid layer, whereas β barrels of EDI and EDII are parallel to the surface (figure 1.4) [81].  
This orientation allows the EDIII to protrude out from the surface and therefore be more 
solvent exposed compared to EDI and EDII.  EDIII consists of anti-parallel β strands and 
loops connecting each of these β strands (figure 1.5) [81].  The highly exposed lateral surface 
of EDIII is collectively made of 3 loops, with the loop connecting EDIII with EDI being 
designated as the N-terminal linker region of EDIII (figure 1.5) [81,90]. 
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The flavivirus E proteins are glycosylated at Asn-153 with an additional 
glycosylation site present at Asn-67 for DENV.  Furthermore, glycosylation at Asn-153 
masks the fusion peptide in the mature virion (figure 1.4)[81].  Although earlier studies 
demonstrated a differential selection of glycosylation sites among different serotypes of 
DENV, recent work from Hacker et al. indicates that both sites are used by all serotypes of 
DENV [93,94].   
 
Conformational changes of E protein  
Flavivirus E proteins undergo major conformational rearrangements from E dimer to 
E trimer before fusion with cellular membrane in the acidic endosome [95].  EDI and EDII 
swing outward keeping EDIII and the stem region preserved in the nearly identical pre-fusion 
orientation.  Later, EDIII is rotated ~200 and the stem region helices are zipped up, driving 
the trimeric E protein into to its fusogenic orientation allowing fusion of the viral membrane 
with the cell membrane [95].  The exogenous addition of recombinant EDIII (rEDIII) blocks 
the fusion of the E protein indicating the important role of EDIII for the rearrangement [96].  
In addition, it has been proposed that protonation of histidine residues at the EDI/III interface 
may initiate the conformational rearrangement or trimerization process [97,98]}.  Therefore, 
it is quite possible that antibodies that bind to the hinge regions between domains of 
monomeric E protein might block the structural rearrangement and thereby neutralize the 
virus at the post attachment step. 
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Known epitopes of Flaviviruses 
The primary target of neutralizing antibodies is the E protein, and neutralization of 
flavivirus is primarily accomplished by either blocking virus-cellular receptor interaction or 
blocking fusion of the viral-cellular membranes [72].  The epitopes of known neutralizing 
Abs are distributed throughout the E protein and located in distinguishable clusters (figure 
1.6 ) [54,72,99-103].  Binding specificities and neutralization capacities of these antibodies 
are varied, and therefore Abs have been grouped into type, sub-complex, complex, sub-group 
and group-specific categories [72].  Most strongly neutralizing antibodies are type-specific, 
and interestingly, many of the strongly neutralizing mAb bind to the lateral ridge of EDIII 
[72,100,103-105]. On the other hand, most of the EDI and EDII binding antibodies are cross- 
reactive antibodies that weakly neutralize the virus, compared to EDIII reactive Abs.  
Therefore, most of EDI/EDII reactive, weakly neutralizing Abs have a potential to induce 
ADE in vitro [72,99,106].  Even though early studies indicated that EDIII antibodies 
neutralize virus by blocking receptor attachment, recent studies conducted with WNV clearly 
showed that EDIII elicits Abs that also block the fusion or post attachment steps [107].  
Monoclonal antibody E16, is a strongly neutralizing type-specific Ab against WNV EDIII, 
which blocks the rearrangement of the E protein in the endosome and consequently blocks 
the fusion step [107].  These findings lead to generalizations such as: 1) E protein is the 
major protein which elicits neutralizing Ab (nAb); 2) E reactive antibodies can either be type 
specific or cross reactive; 3) type-specific Abs strongly neutralize the virus as compared to 
cross-reactive antibodies; 4) the potent, type-specific neutralizing Abs are EDIII-reactive 
whereas EDI and EDII Abs are mostly cross reactive and weakly neutralizing [72,103,106].  
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Occupancy and flavivirus neutralization. 
The average number of Ab molecules required for neutralization has been calculated 
for many viruses [108] and the number required increases with the size of the virion, ranging 
from as low as 4 mAb molecules for polioviruses and up to 225 molecules required for 
neutralizing rabies virus [108].  The neutralization of flavivirus is a multi-hit phenomenon, 
requiring more than one Ab molecule per virion for neutralization [2,68,109].  A molecular 
docking study of the EDIII reactive, strongly neutralizing anti-WNV mAb, E16 revealed that 
this Ab did not bind to all of the E protein monomers in the mature virion [110].  Instead, 
epitopes on 120 E monomers were found to be occupied by the E16 at saturation.  Thirty Ab 
molecules are required for neutralization of WNV, demonstrating that blocking 
approximately 25% of the available 120 E monomers is sufficient to neutralize the virus [68].  
Thus, an antibody that binds to a flavivirus exceeding the threshold value of 30 Ab molecules 
per virion is capable of neutralizing the virus. On the other hand, it is proposed that if the 
maximum number of Ab molecules bound to the virus is below the threshold value, such 
antibodies are unable to neutralize flaviviruses, but may enhance the infection [68].  The 
epitopes on the E protein are not exposed to an equivalent environment on the 3 different 
axes (2-fold, 3-fold and 5-fold axes) of the pseudo-icosahedral symmetry of flavivirus 
envelope protein [13].  Therefore, if the epitope of an antibody is not highly accessible or 
cryptic, even at the maximum occupancy of the available epitopes, such antibody may not be 
able to neutralize the virus [68,109].  Furthermore, dynamic movements of the E protein on 
the virion particles may also be an important factor that determines the accessibility of 
cryptic epitopes and consequently, the stoichiometry and neutralization potential of 
antibodies that bind to cryptic epitopes [111].  
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Type-specific neutralization, known epitopes and their role against DENV infection 
Infection of DENV elicits type-specific, life-long immunity against the homologous 
virus, but not against the heterologous DENVs.  Thus, an individual who has recovered from 
a primary DENV infection against one DENV serotype is still susceptible to sequential 
secondary infections from other DENV serotypes [3].  After a primary infection of DENV, 
the antibodies elicited are mainly against the E protein even though anti prM/M Abs are also 
found [72].  In addition, the presence of Abs against C protein and NS proteins 1, 3 and 5 
have also been reported particularly in secondary DENV infection [112].  Although, anti-
NS1 antibodies are not neutralizing, such Abs are protective through antibody-dependent 
cytotoxicity and complement-mediated clearance [113].  It is proposed that the cross-
reactive, non-neutralizing or weakly neutralizing Abs increase disease severity through ADE, 
especially in a secondary DENV infection [1],  Furthermore, it has been reported that DENV 
immune human polyclonal sera are mainly comprised of antibodies that target the fusion 
loop, which is known to harbor weakly neutralizing mouse mAb epitopes.  However, this 
conclusion was made using western blots with the sera whereby some antibodies that target 
conformational epitopes on other domains of the E protein may not have been detected [114].  
Thus, the mechanism of neutralization and, the epitopes involved in both type-specific 
neutralizing and enhancing Abs in human immune sera, are poorly understood. 
DENV2 and DENV3 are the serotypes that have been isolated most often from severe 
disease epidemics around the world, although all four serotypes of DENV can cause severe 
disease [19,115-117].  However, the neutralization mechanisms of DENV have been mainly 
studied with DENV2, whereas the neutralization of DENV3 is poorly understood.  Anti-
DENV2 mouse mAbs have been well characterized [72,104,118,119].  Most of the epitopes 
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recognized by these mouse mAb are located on all three domains of E protein [72].  As 
already mentioned, the most potent neutralizing mAbs bind to the lateral ridge of EDIII, 
whereas weakly neutralizing and non-neutralizing antibodies mainly target EDII [72].  
However, poorly neutralizing, DENV cross-reactive antibodies have also been mapped onto 
the AB loop of EDIII of DENV2 [118].  Furthermore, EDIII also harbors the epitopes of 
DENV sub-complex Abs, which neutralize more than one DENV serotypes but not all 4 
serotypes, and this epitope is found on the A sheet of EDIII [118,119].  In addition, a recent 
study conducted by Rajamanonmani  and colleagues reported that mouse mAb 9F12, which 
binds to residues mainly located on the A sheet and the BC loop of DENV2 EDIII cross- 
neutralizes all four serotypes of DENV [102].  However, the complete epitopes of these Abs 
have not been identified, and therefore more structural studies with such Abs are necessary to 
identify the neutralizing epitope on EDIII in addition to the type-specific lateral ridge 
epitope.  In contrast, relatively few EDI-reactive antibodies against DENV have been isolated 
and characterized [120,121].  Recently a chimpanzee mAb 5H2, which neutralizes DENV4 
type specifically, has been mapped on EDI at residues 174 and 176 [34].  Furthermore, 
passive transfer of 5H2 protected monkeys from DENV infection.  However, neutralization 
escape mutant viruses with a mutation at AA residue 174 were also isolated from monkeys 
who received 5H2 [34].  Interestingly, genotype III of DENV4 strains isolated from DHF 
patients naturally contained the same AA substitution at 174 of the E protein [34].  This 
finding may suggest that humans also elicit neutralizing Abs which target a similar epitope as 
that of 5H2, and strain variability within DENV4 may interfere with neutralization potential 
of such Abs. Therefore, strain variability may play a role in epitope shuffling, and this may 
induce DHF/DSS as a result of ADE.  Furthermore, a chimpanzee mAb known as 1A5, 
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which efficiently cross-neutralizes DENV1 and DENV2, binds to an epitope located on the 
fusion loop of EDII suggesting that antibodies that target the fusion loop may also neutralize 
virus even though fusion loop Abs are at best only weakly neutralizing [122].  Intriguingly, 
no EDIII-reactive strongly neutralizing Abs were isolated from these non-human primates 
suggesting that EDIII-reactive Abs are rare after DENV infection in primates [34,122]. 
However, the role of EDIII antibodies and the mechanisms of type-specific neutralization 
after natural DENV infection in humans are not well understood. 
 
1.10 Objectives of the study:  
Epidemics of DHF/DSS in Sri Lanka emerged after 1989 with the introduction of a 
new clade of DENV3 genotype 3 [123,124].  However, evolution of other DENV serotypes 
with regard to emergence of severe epidemics in Sri Lanka had never been studied.  
Intriguingly, the numbers of DHF/DSS cases have dramatically increased since 2000 with a 
massive epidemic reported in 2004.  Since the emergence of DHF in Sri Lanka had already 
been linked to the introduction of a novel strain of DENV3, we hypothesized that the recent 
DHF epidemic in 2004 was due to the continuation of evolution of DENV3 or other DENV 
serotypes in Sri Lanka.  Therefore, one goal of the current study was to analyze the molecular 
epidemiology of DENV serotypes over three decades, especially referring to the 2004 
DHF/DSS epidemic in Sri Lanka.  
Studies conducted with mouse mAb had identified the E protein of flavivirus as the 
major immunodominant protein that elicited neutralizing Abs [72].  Interestingly, strongly 
neutralizing type-specific antibodies were shown to be EDIII-reactive.  The central tenet of 
the type-specific neutralization of DENV has been that all the strains that belong to one 
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DENV serotype are uniformly neutralized by the same antibodies [72].  However, 
phylogenetic analyses demonstrated that DENV strains of one serotype display a 
considerable amount of genetic heterogeneicity which can be used to subdivide that serotype 
into genotypes [11].  We hypothesize that strain variation within a serotype of DENV can 
influence the neutralization potential of an Ab.  Therefore, one of the major goals of the 
current research was to determine the effect of intra-serotypic strain variability on 
neutralization by type-specific strongly neutralizing antibodies using DENV3 as a model. 
Although, type-specific strongly neutralizing mouse mAb were shown to bind to the 
lateral ridge of EDIII of flavivirus, it was unclear if the polyclonal immune response from 
flavivirus-infected individuals followed the same.  There are indirect reports to suggest that 
the humoral immune responses after a natural flavivirus infection in humans may be 
different.  Analysis of the human B cell repertoire from WNV-infected individuals suggested 
that the humoral response mainly produces antibodies that target the fusion loop [125], and 
western blot analysis of DENV human immune sera with recombinant E protein also 
revealed the same specificity of human sera [114].  Therefore, a third major goal of the study 
was to determine whether the type-specific neutralization acquired during a natural DENV 
infection was in fact driven by EDIII-reactive, strongly neutralizing antibodies as indicated 
by the mouse monoclonal antibody studies.  
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Figure 1.1 Genome structure of dengue virus and functions of mature   
proteins      
Viral genome is translated to a polyprotein precursor and then cleaved by host and    
viral proteases into 3 structural proteins and 7 non-structural proteins. 
(Adapted from Cell Host Microbe. 2009 Apr 23; 5 (4):318-28) 
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 Figure 1.2 Structure of mature DENV particle 
E protein dimers are arranged in icosahedral symmetry on the surface of the virion. 
The triangle shows an icosahedral unit with 5 fold, 3 fold and 2 fold axes. EDIII 
protrudes out from the surface of the virion (arrow).  
(Adapted from ftp://ftp.purdue.edu/pub/uns/kuhn.dengue1.jpeg) 
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Figure 1.3 Life cycle of dengue virus. 
A. Different stages of the life cycle of DENV along with the pH of the  
different components of the secretory pathway are shown.  B. Major conformational  
rearrangements of the E protein in the maturation  process of DENV.  
(Adapted from Antiviral Research Volume 81, Issue 1, January 2009, Pages 6-15)  
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Fig 1.4 Structure of DENV E protein 
A. Three domains of E protein. EDI is Red, EDII is Yellow and EDIII is Blue. Amino 
acids 1-392 form the ectodomain of E protein. Amino acids 392-494 form the stem 
region and the trans-membrane domain of E protein. B.  Ectodomain of E protein 
viewed from the top (2 fold symmetry axis). C.  Side view of E protein ectodomain 
(perpendicular to 2 fold axis). Two glycans on residues 67 and 153 of the sub units A 
and B are labeled. D. Ecotodomain of E is connected to the TM domain by the stem 
region containing two amphipathic helices, which are partially buried in the outer 
leaflet of lipid bilayer. (Adapted from J Virol. 2005;79(2):1223-31 and Nature 
Reviews Microbiology. 2005; 3: 13-22) 
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 Figure 1.5 Structure of DENV3 EDIII. 
            EDIII consists of seven β strands linked by connecting loops. The β strands are   
            labeled from A to G. The lateral ridge of EDIII is collectively made of 3 loops (DE,   
            BC, FG loops) with the N’ terminal linker region.  
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                  Figure 1.6 Distribution of known neutralizing epitope on E protein 
                  All three domains of E protein contain epitopes recognized by mouse mAb.  
                  Each circle represents a cluster of epitope (Adapted from Cell Host  
                  Microbe.2008;4(3):229-38) 
              
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Chapter 2 
Phylogenetic analysis of dengue virus in Sri Lanka from 1981 to 2006 with a special 
reference to the severe epidemic in 2004. 
 
 
[Kanakaratne N, Wahala WMPB, Messer WB, Tissera HA, Shahani A, Abeysinghe N, et al. 
Severe dengue epidemics in Sri Lanka, 2003–2006. Emerg Infect Dis, 2009;15: 192-199 
Collection of serum samples, clinical information, epidemiological data and diagnosis of 
DENV in serum by PCR were carried out by Karunartahne and colleagues in Sri Lanka.  
Virus isolation from PCR positive samples, genotyping of virus isolates, designing of PCR 
primers for gene sequencing, gene sequencing, phylogenetic analysis of DENV and 
interpretation of phylogram, were carried out by Wahala WMPB.] 
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2.1 Abstract  
Recent emergence of dengue hemorrhagic fever in the Indian subcontinent has been 
well documented in Sri Lanka. We analyzed the phylogenetic relationship of dengue virus 
(DENV) during a severe epidemic during 2003-2006 in Sri Lanka by comparing the virus 
isolates over a period of three decades. The four serotypes of DENV have been cocirculating 
in Sri Lanka and their distribution has not changed over 30 years. During this period, 
DENV1 and DENV4 showed a genotype switch, which is not observed in the phylogeny of 
DENV2 and 3. Instead, new clades of DENV3 genotype III viruses have replaced older 
clades and DENV2 also showed a similar trend. Emergence of new clades of DENV3 in 
1989 and 2000 coincided with abrupt increases in the number of reported dengue cases, 
implicating this serotype in severe epidemics. 
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2.2 Introduction: 
Dengue virus, a member of family Flaviviride, comprises four different viruses 
designated DENV serotype 1 (DENV1) through DENV serotype 4 (DENV4).  Each serotype 
of DENV is further sub-divided into genotypes depending on nucleic acid sequence 
similarities [1].  An infection of DENV leads to a wide range of disease symptoms from mild 
dengue fever (DF) to more severe, life threatening dengue hemorrhagic fever (DHF) and 
dengue shock syndrome (DSS) [2].  Aedes aegypti and Ae. albopictus are the main mosquito 
vectors that transmit DENV [3].  Dengue viruses are now widely spread over the tropics and 
subtropics causing a major global health problem [4].  Globalization, urbanization, increase 
of mosquito density in urban settings and especially global travel of dengue viremic people 
are among the factors that contributed to the global spread of DENV [3-6].  
Pathogenesis of DHF/DSS is poorly understood mainly due to the lack of a well 
defined animal model.  However, prospective and retrospective human cohort studies have 
indicated that secondary infection of DENV is a major cause for DHF/DSS, although the 
exact mechanism that causes DHF/DSS is not known [7-11,12 ,13,14].  In addition to 
secondary infection, many virus and host genetic factors are involved in determining disease 
severity [15-18].  Differences in virulence among different DENV serotypes and genotypes 
have contributed to severe disease in human [17-19].  Differences of virulence in two 
genotypes of DENV2 have been well documented [17].  The Asian genotype of DENV2  is 
more likely to cause DHF compared to the American genotype of DENV2.  Furthermore, 
studies have revealed that differences in amino acid sequence of the envelop (E) gene and the 
untranslated regions of the genome (UTR) correlated with the differences in replication and 
virus output between these two genotypes of DENV2, respectively [20-22].  
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Phylogenetic analysis of DENV strains has been used to understand the evolution of 
the virus as well as its association with severe disease outbreaks [23]. Whole genome, or 
partial genome sequences have been used for these analyses with the same outcome [1,24].  
Therefore, most of the phylogenetic studies with DENV have been conducted by analyzing a 
portion of the DENV genome. Such analyses revealed that turnover of new viral lineages or 
clades is a regular occurrence, and sometimes, clade replacement has been correlated with 
different disease outcome [23,25-31]  
After 1989, recurrent DHF epidemics have been reported in Sri Lanka, an island 
located in the Indian subcontinent [32].  Although the number of DHF/DSS cases has 
increased after 1989, the intensity of dengue transmission and the relative abundance of each 
serotype have remained unchanged [32].  However, DHF has now become a regular 
occurrence on the island.  The magnitude of the epidemics has increased over time, and 
especially large island-wide epidemics occurred in 2000, 2004 and 2009 (figure 2.1).  
 The phylogenetic analysis of viruses isolated from 1981 to 1997 clearly grouped 
DENV3 into two clades designated pre-DHF and post-DHF viruses [19].  Messer et al 
proposed that the sudden appearance of DHF epidemics in the island was related to the 
introduction of a new clade of DENV3 [19].  Although both DENV2 and 3 predominated in 
the period of these studies along with low circulation rates of DENV1 and 4, the 
phylogenetic relationships among DENV serotypes other than DENV3 are not known 
[19,32].  Therefore, molecular epidemiology of all serotypes of DENV from 1981 to 2004 
was examined in the current study to understand viral evolution over this time and its 
contribution to one of the largest DENV epidemics that occurred in 2004 in Sri Lanka. 
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2.3 Materials and Methods: 
Sample Collection 
Genetech Molecular Diagnostics Institute (GMDI) in Colombo, Sri Lanka, receives 
diagnostic specimens for dengue testing from clinics and hospitals in Colombo. This study 
used excess serum samples that remained after diagnostic testing. Only samples collected 
from patients with 1–4 days of fever were included in the study. All patient-identifying 
information was removed from specimens before their use in the study. The study was 
reviewed and approved by the Institutional Review Boards of the University of North 
Carolina, Chapel Hill, NC, USA, and the University of Sri Lanka, Peradeniya, Sri Lanka. 
 
Reverse Transcription–PCR for Detection and Serotyping of DENVs  
Reverse transcription–PCR was performed at GMDI by using the DV1 and DV3 
primer set  and the ALD 1 and ALD 2 primer set  in one reaction [33,34].  The DV primers 
amplify a 470-bp fragment of the nonstructural protein 3 (NS3) gene of all flaviviruses. The 
ALD1 and ALD2 primers amplify a 229–240-bp product from the 3´ untranslated region of 
all DENVs. The DV primers were not as sensitive as the ALD primers for detecting dengue 
infection. However, the 470-bp fragment amplified by the DV primers was used as the 
template in a second nested PCR to serotype the virus. All the virus isolates and a subset of 
PCR positive samples were also serotyped by using D1,D2 and TS1-TS4 primers using semi-
nested multiplex PCR  at University of North Carolina at Chapel Hill (UNC CH) [35] 
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Isolation of DENV from acute serum samples: 
Different parameters were optimized to increase the isolation rate of DENV from 
acute serum samples.  Briefly, 15 µL from PCR positive serum was mixed with 185 µl of 
minimal essential medium containing 2% fetal bovine serum and added to C6/36 cells 
growing in 6-well tissue culture plates. The inoculum was incubated for 1 hour at 28C and 2 
ml of media was added.  Plates were incubated for 10 days in a CO2 incubator at 28C.  Cells 
were tested for DENV by staining with monoclonal antibody 4G2, which binds to the 
envelope (E) protein of all 4 DENV serotypes. Supernatants were harvested from positive 
wells and frozen as P1 DENV stocks in the presence of 20% FBS. 
 
Sequencing and Phylogenetic Analysis of DENV: 
The P1 virus stocks were used as a source of RNA for sequencing and genotyping 
viruses. Before genotyping, the serotype of each virus isolate was confirmed by PCR using 
semi-nested PCR with D1, D2, TS1, TS2, TS3 and TS4 primers [35]. Once the serotype of 
the isolates was confirmed, reverse transcription–PCR (RT-PCR) was performed with 
different primer pairs to amplify selected regions of the genome of DENV1-4.  For DENV-1, 
a 536-bp segment at the envelope-NS1 junction was amplified by using primers D1F 2034–
2055 (5´-CCTTTTGGTGAGAGCTACATCG-3´) and D1R 2570–2551 (5´- 
ACACACACCCTCCTCCCATG-3´). For DENV-2, we amplified a 519-bp segment at the E-
NS1 junction by using primers D2F 2050–2071 (5´-CCATTCGGAGACAGCTACATCA-3´) 
and D2R 2569–2548 (5´-GAGCCTTCTGGATAGCTGAAGC-3´). A 1,057-bp segment 
encompassing part of the capsid (C) protein, the premembrane (prM) protein, and part of the 
E protein of DENV3 was amplified by using primers D3F 132–159 (5´- 
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TCAATATGCTGAAACGCGTGAGAAACCG-3´) and D3R 1189–1171 (5´- 
CTCCTCAGGCAAAACCGCT-3´).  A 962-bp segment encompassing part of the C protein, 
prM protein, and part of the E protein of DENV4 was amplified by using primers D4F 137–
162 (5´-TCAATATGCTGAAACGCGAGAGAACCG 3-´) and D4R 1099–1074 (5´-
CCACTTCCTTGGCTGTTGTCTTGATC-3´). 
PCR products were gel purified using QIAEX II Gel Extraction Kit (Qiagen, 
Valencia, CA, USA) according to the manufacturer’s instruction and sent to the University of 
North Carolina–Chapel Hill Genome Analysis Facility. Overlapping individual nucleic acid 
sequences were assembled by using Vector NTI (ContigExpress, Bethesda, MD, USA). 
Sequences were aligned by using ClustalX (www.clustal.org), and pylogenetic analyses were 
conducted by, PHYLIP (http://evolution.gs.washington.edu/phylip.html), and MEGA4 
(www.megasoftware.net) software [36,37].  The evolutionary history of each DENV serotype 
was inferred by using the minimum- evolution method [38].  Percentages of replicate trees, in 
which the associated taxa are clustered in the bootstrap test (1000 replicates), are shown next 
to each branch of the phylogram.  All new viral sequences were deposited in GenBank (gene 
bank accession number FJ225443 - FJ225471).  The virus strains used to create phylogenetic 
trees are summarized in table 2.1. 
 
2.4 Results: 
Circulating Dengue Serotypes in Sri Lanka: 
Of 930 PCR-positive samples collected during 2003–2006, 605 samples were sero-
typed by nested PCR. DENV serotypes 2 (40%) and serotype 3 (46%) were common, and 
serotypes 1 (7%) and 4 (7%) were rare.  We examined the relative abundance of each 
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serotype at monthly intervals during October 2003–September 2006 (Figure 2.2).  DENV2 
and DENV-3 were the dominant serotypes throughout the study period.  DENV1 and 
DENV4 were also regularly isolated but in low numbers.  All 4 serotypes were detected in 
2004 and 2006.  In 2005, DENV activity was low and DENV1 was not identified in samples. 
These results demonstrate that although all 4 serotypes co-circulate in Sri Lanka, DENV 
serotypes 2 and 3 are predominantly responsible for clinically apparent cases. 
 
Isolation of DENV from acute serum samples: 
Initial attempts to isolate DENV virus from a subset of PCR positive acute serum 
samples using standard protocols were successful only for some serum samples.  We noticed 
that most of the serum samples contained an unidentified serum components that was toxic to 
C6/36 cells.  After titrating the amount of serum and the duration of incubation with the 
C6/36 cells at 28C, the optimum conditions for isolation of DENV from acute serum samples 
were identified and given in detail in the Materials and Methods section.  The optimized 
protocol was successfully used to isolate DENV from acute serum samples with an isolation 
rate of  82 % (181of 220). Each virus isolate was sero-typed by semi-nested PCR.  The 181 
isolates consisted of 18 DENV1 strains, 76 DENV2 strains, 64 DENV3 strains, and 23 
DENV4 strains.  It has been reported by others that adaptation of C6/36 to 33C has increased 
the replication rate of DENV and consequently increased the isolation rate from acute serum 
samples [39,40].  Although the recovery rate of the present study was also high, optimizing 
virus isolation at higher temperature may contribute to a further increase in the rate of 
isolation.  
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Phylogeny of DENVs in Sri lanka 
The emergence of DHF epidemics in Sri Lanka after 1989 was closely correlated with 
a replacement of the non-pathogenic clade of DENV3 genotype III by a pathogenic clade of 
the same genotype.  Subsequently, these two clades were designated pre-DHF or genotype 
IIIA and post-DHF or genotype IIIB viruses [19].  In addition, viruses belonging to the post-
DHF clade of DENV3 genotype III have also been introduced to Latin Amaerica leading to 
severe DHF epidemic in these regions as well [19].  Although DHF emerged in Sri Lanka 
after 1989, the number of cases and deaths was low until 2000.  A rapid increase of DF/DHF 
cases and the number of deaths have been documented in 2000 and thereafter (figure 2.1).  
Therefore, phylogenetic analysis of representative virus strains isolated between 1981 and 
2004 were conducted to further characterize the DENVs responsible for recent epidemics in 
Sri Lanka after 2000, and to identify genotypes of DENV that have been circulating in this 
country over three decades from 1980s. All virus strains and sequences used for this analysis 
are listed in the table 2.1.  Phylogenetic grouping of DENV serotypes and their nomenclature 
are based on that described by Rico-Hesse [41].  Genotypes are named on the basis of 
country of origin of the earliest isolates and not necessarily on the current distribution of 
viruses. 
 
Phylogeny of DENV1 during 1983–2004: 
DENV1 has been subdivided into 4 genotypes designated South Pacific, Asia, 
Thailand, and Africa/America [41].  A 498-nt fragment at the E/NS1 junction (from positions 
2056 to 2554) was used to create a phylogenetic tree with virus isolates obtained in 1983, 
1984, 1997, 2003, and 2004. Results demonstrate that the DENV-1 genotype circulating in 
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Sri Lanka has changed over the study period. The two isolates from Sri Lanka obtained in 
1983 and 1984 belonged to the South Pacific genotype (Figure 2.3).  The phylogenetic tree 
further indicates that the South Pacific genotype was replaced by the Africa/America DENV1 
genotype sometime during 1984–1997.  The number of Sri Lankan DENV1 isolates as well 
as their temporal distribution is limited in the analysis and therefore, clade turnover cannot be 
identified temporally.  
 
Phylogeny of DENV2 during 1981–2004: 
DENV-2 has been subdivided into 4 genotypes designated Malaysian/Indian 
subcontinent, Southeast Asian, American, and West African (Sylvatic) [41].  The Sri Lankan 
DENV-2 strains in our collection were isolated in 1981, 1982, 1983, 1984, 1985, 1989, 1990, 
1996, 1997, 2003, and 2004.  Nucleic acid sequences from a 240-nt fragment at E/NS1 
junction (nt positions 2311–2550) were used to generate a phylogenetic tree along with 
existing sequences in GenBank representing all genotypes of DENV2 strains.  All DENV2 
isolates from Sri Lanka were closely related and belong to the Indian subcontinent/Malaysia 
genotype (figure 2.4).  Moreover, there is no evidence for the recent introduction of a 
DENV2 strain from outside the island, because the DENV-2 strains from Sri Lanka are more 
closely related to one another than to any other DENV-2 strain used in this analysis. 
 
Phylogeny of DENV3 during 1983–2004: 
DENV3 has been divided into 4 genotypes designated Southeast Asian/South Pacific 
(I), Thailand (II), Indian subcontinent (III), and American (IV) [41,42].  Previous studies 
have demonstrated that all DENV-3 strains from Sri Lanka isolated in the 1980s and 1990s 
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were categorized into the Indian subcontinent genotype (III) [19,42].  Within genotype III, 
DENV3 strains from Sri Lanka form two distinct clades linked to mild (pre DHF or IIIA 
clade) and severe (post DHF or IIIB clade) disease epidemics on the island [19].  DENV-3 
IIIB viruses are likely to have been introduced from East Africa [19].  In 1994, a DENV-3 
genotype III from South Asia or East Africa was also introduced into Latin America where it 
is now well established and responsible for severe disease epidemics [19]. 
Considering the backdrop of the recent expansion of DENV-3 genotype III viruses, 
the relationship of DENV-3 genotype III strains from Sri Lanka isolated in 2003 and 2004 to 
other DENV-3 genotype III viruses currently circulating in Africa, the Americas, and the 
Indian subcontinent was determined.  A 966-nt fragment from a portion of C, all of preM, 
and a portion of E gene (nt positions 179–1144) was sequenced.  A phylogenetic tree was 
created by using new sequences and existing sequences in GenBank from representative 
DENV-3 genotype III strains (figure 2.5).  The DENV-3 sequences used were from isolates 
obtained in Sri Lanka in 1983, 1984, 1985, 1989, 1990, 1993, 1994, 1997, 1998, 2003, and 
2004.  As previously demonstrated, genotype III of DENV3 consists of pre-DHF (IIIA) and 
post-DHF (IIIB) clades from Sri Lanka, as well as Latin American and East African clades 
(figure 2.5  and figure by Messer et al [19]).  However, DENV3 strains from Sri Lanka 
isolated in 2003 and 2004 form a new, distinct clade that is closely related but distinct from 
the DENV3 post-DHF clade (IIIB) viruses that were isolated in the 1990s.  Therefore, pre 
DHF (IIIA) and post-DHF (IIIB) clades were re-named as pre-1989  clade and post-1989  
clade respectively.  The new 2003–2004 clade, which is designated post-2000 clade, includes 
an isolate from 1993 indicating that post-2000 clade viruses have emerged from a previously 
rare virus present in Sri Lanka. In addition, after 1993, the earliest isolate of the post-2000 
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clade virus was reported in 2000 [43].  The data of the current analysis indicate that post- 
2000 clade viruses have probably re-appeared in 2000 and replaced the post-1989 viruses. 
 
Phylogeny of DENV4 during 1978–2004: 
The phylogeny of DENV4 has not been studied as extensively as the other serotypes. 
This serotype can be broadly separated into two genotypes designated Southeast Asian (I) 
and Indonesian (II) [41].  The Southeast Asian genotype strains are primarily from Asia, 
whereas the Indonesian group has a broad distribution in Asia and the Americas. A 296-nt 
fragment from positions 787–1083 (prM/E junction) was used to create a phylogenetic tree. 
A DENV4 isolate obtained in 1978 was grouped into the Southeast Asian genotype or 
genotype I.  Unfortunately, no virus isolates were available to represent the period from 1979 
to 1991, and therefore, the distribution of DENV4 genotypes during 1979-1991 is not known.  
However, as depicted in figure 2.6, two virus isolates obtained in 1992 belonged to the 
Indonesian genotype indicating the introduction of the Indonesian genotype to Sri Lanka.  
DENV4 isolates collected during 2003-2004 epidemics again fell into the Southeast Asian 
genotype, suggesting that the Southeast Asian genotype is the predominant DENV4 in Sri 
Lanka and the Indonesian genotype probably became extinct after a transient introduction.  
However, since the no virus isolates were not obtained  between  1979-1991 and 1993-2002, 
temporal distribution of DENV4 genotypes is not conclusive, although the Southeast Asian 
genotype seems to be  the predominant. It is quite possible that, after introduction of the 
Southeast Asian genotypes in the 1970s, the genotype might have been replaced by the 
Indonesian genotype in the 1990s and again, the Southeast Asian genotype was re-introduced 
in 2000 by replacing the Indonesian genotype. 
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2.5 Discussion: 
Introduction of new strains has been considered as one reason for the emergence of 
severe DF/DHF epidemics in the world [17,19,25,30,44,45].  Phylogenetic analysis has been 
widely used to determine the distribution of virus strains over time and to study the evolution 
of DENV [6,46].  Although dengue virus infection is one of the major health concerns in the 
Indian subcontinent, the disease and its viruses remains poorly studied in the region [47-50].  
Furthermore, the epidemiology of dengue has changed over time, and recurrent DF/DHF 
epidemics are now common in the region [19,51-55].  In Sri Lanka, major DF/DHF 
epidemics appeared after 1989, and ever since, the frequency as well as the severity of 
DF/DHF epidemics has increased.  In 2000, the number of DF/DHF cases significantly 
increased compared to the late 1990s, leading to a massive epidemic in 2004 (figure 2.1).  
Moreover, the trend to severe DF/DHF epidemic has further increased, and in the first 6 
months of 2009, 11,000 cases and 160 deaths have been reported (figure 2.1).  Therefore, a 
better understanding of epidemiology of dengue virus in the region is important to develop 
and implement effective control programs, and to effectively use future dengue vaccines, 
which are currently in phase 2 clinical trials. 
Data from the current study indicates that the relative frequency of DENV serotypes 
during 2003 - 2006 epidemics was not distinct from the frequency reported earlier in Sri 
Lanka.  DENV2 and DENV3 were the predominant viruses before 1999, with the incidence 
of DENV2 being marginally higher than DENV3 [32].  In the severe epidemic period in 
2004, DENV3 was the predominant serotype followed by DENV2 (figure 2.2).  However, 
according to Kularathne et al, proportion of DENV2 had dramatically increased during 1999-
2001 compared to DENV3, although DENV3 dominated over DENV2 in the severe DF/DHF 
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epidemic in 2004 [56].  This high incidence of DENV2 may be due to sampling bias and the 
small number of samples studied.  However, it is obvious that DENV2 and DENV3 are the 
most dominant DENV serotypes in Sri Lanka followed by DENV1 and DENV4, 
respectively, throughout the study period (figure 2.2 and Messer et al [32]). 
The present study revealed that a new clade of DENV3 in genotype III (post-2000 
clade) has become dominant on the Island after 2000.  Among the hypotheses to explain the 
emergence of new DENV variants are adaptive selections due to immune pressure [26,57], 
purifying selection [58], stochastic events [59], and a genetic bottleneck in the mosquitoes 
that leads to selection of  a  virus variant with a high fitness [46].  However, none of these 
hypotheses can universally explain the appearance of new DENV variants in different 
epidemics around the world.  In fact, it has been shown that adaptive selection, especially in 
DENV3, is very rare although few studies claimed that such selection has led to emergence 
of new DENV2 variant [26,57].  Genetic bottlenecks, especially in the inter-epidemic period, 
have been proposed to be important for emergence of new variants or lineages of DENV3 
[60].  
 Both pre-1989 and post-1989 clade DENV3 viruses co-circulated in Sri Lanka in 
1989 [19].  However, post-1989 clade viruses disseminate efficiently in mosquitoes [61] and  
probably have gained high fitness [61].  Therefore, genetic bottleneck might have been a 
factor for post-1989 viruses to replace the pre-1989 clade.  However, again in 2000, the post- 
2000 DENV3 clade has emerged with increased spread and severity of dengue epidemics.  
Therefore, clade replacements in 1989 and again in 2000 were both linked to stepwise 
increases in the number of DF/DHF cases reported in Sri Lanka.  However, further research 
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is needed to understand the underlying mechanisms by which post-2000 clade viruses have 
replaced the post-1989 clade. 
Phylogeny of DENV2 was not drastically changed over the period studied.  However, 
even though all of the strains used in the study grouped into the Indian subcontinent 
genotype, a clear pattern of temporal distribution of DENV2 within the Indian subcontinent 
genotype was observed.  The pattern of subgrouping of DENV2 within the Indian 
subcontinent genotype is similar to the grouping of DENV3 into different clades within 
genotype III, indicating pre-1989, post-1989 and post-2000 groups (figure 2.4 and figure 
2.5).  However, the bootstrapping value in the phylogenetic tree is not strong enough to 
designate them into different clades.  This may be partly due to the short length of the nucleic 
acid sequence (240 nucleic acids) used for phylogenetic analysis of DENV2.  Therefore, 
further research is needed to understand the evolution of DENV2 in Sri Lanka 
DENV1 and DENV4 showed a genotype shift over the study period, which has not 
been observed in the phylogeny of DENV2 and 3.  However, the limited number of virus 
isolates, which was not evenly distributed over the study period, hampered the understanding 
of the evolution of DENV1 and 4 (figure 2.3 and 2.6).  However, the phylogenetic analysis 
demonstrated the South Pacific genotype of DENV1, which dominated in the 1980s, was 
replaced by the introduction of the African/American genotype which is now established as 
the predominant DENV1 genotype in Sri Lanka after the 1990s (figure 2.3).  Interestingly, 
the South Asian genotype of DENV4, which was present as the predominant genotype in Sri 
Lanka throughout the study period, was interrupted by the transient introduction of the 
Indonesian genotype in the early 1990s.  
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In summary, our data along with previously published data [19] indicate that DENV2 
and DENV3 are the predominant virus strains co-circulating in Sri Lanka, and the 
introduction of new clades, especially new clades of DENV3, are linked with the severe 
epidemics in Sri Lanka over the study period.  However, apart from the phylogeny of virus, 
the exact mechanisms involved in the introduction and selection of new clades were not clear 
from these studies.  It is known that the mosquito infection rate is higher during epidemics 
than in the interepidemic phase [62].  In addition, virus strains involved in silent DENV 
infection (asymptomatic DENV infection) during the interepidemic phase have been 
considered as  predictive of the next epidemic [62].  However, very few studies have been  
conducted to study any of these parameters in Sri Lanka [63-66].  Most of the information 
relating to the 1980s and 1990s has been derived from retrospective studies [32].  Although 
these studies have revealed the overall distribution of different DENV serotypes, turnover of 
new genotypes or clades cannot be analyzed by such studies. Therefore, it is important to 
study asymptomatic DENV infection along with vector studies, especially in the 
interepidemic period, to understand how new virus strains are circulating in a DENV hyper-
endemic country like Sri Lanka.  Understanding mechanisms involved in evolution of DENV 
in Sri Lanka may help to predict future epidemics. 
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 Taxon name Source of  sequence 
Accession 
number 
DENV1 DV1 West Pacific 1974 Genbank U88535 
 DV1 Aust 1983 Genbank AB074761 
 DV1 Japan 1943 Genbank AB074760 
 DV1 China 1980 Genbank AF350498 
 DV1 Thailand 1964 Genbank AF180818 
 DV1 Thailand 1958 Genbank D10513 
 DV1 Abidjan Genbank AF298807 
 DV1 Nigeria  1968 Genbank AF425625 
 DV1 Brazil 2001 Genbank AF513110 
 DV1 Brazil 1997 Genbank AF311956 
 DV1 Brazil 1990 Genbank AF226685 
 DV1 Malaysia (Sylvatic) 1972 Genbank EF457905 
 DV1 SL 1983 This study FJ225443 
 DV1 SL 1984 This study FJ225444 
 DV1 SL 1992 This study FJ225445 
 DV1 SL 1997 This study FJ225446 
 DV1  SL 2003a This study FJ225447 
 DV1  SL 2004a This study FJ225448 
 DV1  SL 2004b This study FJ225449 
 DV1 SL 2004c This study FJ225450 
    
DV2 DV2 Senegal (sylvatic) 1974 Genbank M32957 
 DV2 Mexico 1992 Genbank U91888 
 DV2 Venezuela 1993 Genbank U91870 
 DV2 Colombia 1992 Genbank U91876 
 DV2 Jamaica 1981 Genbank M32950 
 DV2 Brazil 1991 Genbank U91867 
 DV2 Thailand 1983 Genbank M32947 
 DV2 Thailand 1964 Genbank M32941 
 DV2 Taiwan 1987 Genbank M32949 
 DV2 Philippines 1988 Genbank M32932 
 DV2 Seychelles 1973 Genbank M32952 
 DV2 Bukina Faso 1982 Genbank M32956 
 DV2 Indonesia 1978 Genbank M32934 
 DV2 SL 1981 Genbank M32938 
 DV2 SL 1982 Genbank M32940 
 DV2 SL 1983 This study FJ225451 
 DV2 SL 1984 This study FJ225452 
 DV2 SL 1985 Genbank M32953 
 DV2 SL 1989a This study FJ225453 
 DV2 SL 1989b This study FJ225454 
 DV2 SL 1990 This study FJ225455 
 DV2 SL 1996 This study FJ225456 
 DV2 SL 1997 This study FJ225457 
 DV2 SL 2003a This study FJ225458 
 DV2 SL 2003b This study FJ225459 
 DV2 SL 2004a This study FJ225460 
 DV2 SL 2004b This study FJ225461 
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Table 2.1. DENV strains and the source of the sequence used in the study 
Table 2.1:  Continued 
 Taxon name Source sequence Accession number 
DV3 DV3 SL 2003a This study FJ225463 
 DV3 SL 2004a This study FJ225464 
 DV3 SL 2004b This study FJ225465 
 DV3 SL 1983a Genbank AF547225 
 DV3 SL 1983b Genbank AF547227 
 DV3 SL 1983c Genbank AF547228 
 DV3 SL 1983d Genbank AF547229 
 DV3 Mozambique 1985 Genbank AF547237 
 DV3 SL 1985a Genbank AF547241 
 DV3 SL 1985b This study FJ225462 
 DV3 SL 1989a Genbank AF547230 
 DV3 SL 1989b Genbank AF547231 
 DV3 SL 1989c Genbank AF547232 
 DV3 SL 1990 Genbank AF547233 
 DV3 Kenya 1991 Genbank AF547239 
 DV3 Somalia 1993 Genbank AF547240 
 DV3 SL 1993 Genbank AF547234 
 DV3 Panama 1994 Genbank AF547247 
 DV3 Sl 1994 Genbank AF547235 
 DV3 SL 1997 Genbank AF547242 
 DV3 El Salvador 1998 Genbank AF547259 
 DV3 Nicaragua 1998 Genbank AF547245 
 DV3 Puerto Rico 1998 Genbank AF547258 
 DV3 SL 1998 Genbank AF547243 
 D3H-87 Genbank M93130 
    
DV4 DV4 Dominica 1981 Genbank AY152360 
 DV4 Thailand 1991 Genbank AY618990 
 DV4 Thailand  2001 Genbank AY618992 
 DV4 Thailand  1977 Genbank AY618991 
 DV4 Malaysia (Sylvatic) 1975 Genbank EF457906 
 DV4 China Genbank AF289029 
 DV4 Indonesia 1976 Genbank U18429 
 DV4 Tahiti 1979 Genbank U18438 
 DV4 Sri Lanka 1978 Genbank AY550909 
 DV4 SL 1992a This study FJ225466 
 DV4 SL 1992b This study FJ225467 
 DV4 SL 2003a This study FJ225468 
 DV4 SL 2003b This study FJ225469 
 DV4 SL 2004a This study FJ225470 
 DV4 SL 2004b This study FJ225471 
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Figure 2.1: Temporal distribution of number of DF/DHF cases and deaths from 1980 to 
June 2009. 
Before 1989 (pre 1989 period), no DHF cases and deaths were reported in Sri Lanka. Post 1989 
period started with the introduction of DHF along with post 1989 DENV3  viruses to Sri Lanka in 
1989 (*). In post 2000 period, starting in 2000 (**), number of DF/DHF cases were dramatically 
increased with a peak epidemic in 2004 (●) and an ongoing epidemic in 2009 (●●). Information 
was collected with the courtesy of epidemiology unit, ministry of health, Sri Lanka 
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Figure 2.2: Monthly distribution of DENV serotypes identified in patient’s sera 
collected from January 2003 to September 2006: All the PCR positive serum samples 
were serotyped by semi nested PCR and total number of each DENV serotype was 
graphed on monthly basis. May to August and November to January are the two seasonal 
peaks of DENV appearing each year. 
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Figure 2.3: Phylogram of dengue serotype 1 viruses (DENV-1) from Sri Lanka 
(SL), 1983–2004, and other DENV-1 viruses. The tree is based on a 498-bp fragment 
for positions 2056–2554 coding portions of envelope protein and nonstructural protein 
1. The tree was rooted by using a DENV-1 sylvatic strain. Classification and naming of 
different DENV-1 genotypes is based on the report by Rico-Hesse [41]. Scale bar 
represents number of base substitutions per site. 
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Figure 2.4: Phylogram of dengue serotype 2 viruses (DENV-2) from Sri Lanka (SL), 
1981–2004, and other DENV-2 viruses. The tree is based on a 239-bp fragment for 
positions 2311–2550 coding for amino acids at the envelope protein/nonstructural protein 1 
junction. DENV-2 sylvatic strain was used to root the phylogenetic tree. Classification and 
naming of different DENV-2 genotypes is based on the report by Rico-Hesse [41]. Scale bar 
represents number of base substitutions per site. 
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Figure 2.5: Phylogram of dengue serotype 3 (DENV-3) genotype III viruses from Sri 
Lanka (SL), 1981–2004, and other DENV-3 genotype III viruses. The tree is based on a 
966-bp fragment for positions 179–1144 coding for a portion of the capsid protein, all of the 
premembrane protein, and a portion of the envelope protein. Phylogenetic tree was rooted 
by using a DENV-3 genotype I virus (H87). Naming of the different groups within DENV-3 
genotype III is based on the report by Messer et al. [19]. Scale bar represents number of 
base substitutions per site. 
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Figure 2.6: Phylogram of dengue serotype 4 viruses (DENV-4) from Sri Lanka (SL), 
1978–2004, and other DENV-4 viruses. The tree is based on a 296-bp for positions 787–
1083 coding for portions of premembrane and envelope proteins. The tree was rooted by 
using a sylvatic DENV-4 strain. Classification and naming of different DENV-4 genotypes 
is based on the report by Rico-Hesse [41]. Scale bar represents number of base substitutions 
per site. 
  
 
 
CHAPTER 3 
Development of mouse monoclonal antibody (mAb) against dengue virus serotype 3. 
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3.1 Abstract :  
The mechanism of Dengue virus serotype 3 neutralization is poorly understood 
although it causes major epidemics in South Asia and Americas.  This is mainly due to 
the dearth of monoclonal antibodies (mAb) against DENV3.  We developed a panel of 
mouse mAb against DENV3 strain CH53489.  The panel of mAb includes DENV type- 
specific, DENV cross-neutralizing and non-neutralizing mAbs.  This panel of mAbs is a 
valuable tool to study the mechanism of DENV3 neutralization and in other DENV 
studies. 
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3.2 Introduction:  
The neutralization mechanism of flavivirus has been mainly studied with 
reference to West Nile virus (WNV), especially using the mAb E16 [1,2].  Many other 
studies conducted with DENV2, Japanese encephalitis virus (JEV) and tick born 
encephalitis virus (TBEV) have also confirmed that neutralization of flavivirus is 
mediated bya  multi-hit mechanism that requires more than 30 Ab molecules per virion 
[1,3,4].  However, most of these studies were conducted with EDIII reactive antibodies.  
Interestingly, a considerable amount of amino acid (AA) heterogenicity of E protein is 
found among the members DENV3 genotypes, and many of them are located on EDIII 
(Chapter 4).  Such AA heterogenicity may interfere with the neutralization potential of 
DEV3 type-specific antibodies or polyclonal sera among the members of the DENV3 
serotype [5].  
Even though monoclonal antibodies (mAb) are valuable tools to investigate the 
mechanisms of neutralization of flavivirus and other viruses as well , not many DENV3 
type-specific mAb are available except the mAb 1H9 [6].  Therefore, a shortage of type- 
specific mAb against DENV3 has hampered studies of neutralization mechanisms of 
DENV3, especially to determine whether strain variability affects the neutralization 
potential of DEN3 type specific antibodies.  The aim of the present study was to develop 
type specific as well as cross reactive neutralizing mouse mAb against all the domains of 
E protein of DENV3.  We were able to isolate mouse mAb that bound to different 
domains of the E protein and that displayed different potentials of neutralization 
capacities.  
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3.3 Materials and Methods: 
Purification of DENV. 
DENV3 CH53489 reference strain (genotype II) was grown in Vero-81 cells 
(ATCC CCL-81) at 37C.   The virus containing media was harvested 5-7 days after 
infection and centrifuged to pellet cell debris.  The clarified medium was layered on top 
of a 20% sucrose (wt/vol in PBS) cushion and centrifuged (72,000g for 5 hrs) to pellet 
the virus.  The virus pellet was allowed to dissolve overnight in PBS before layering on a 
10%- 40% iodixanol gradient in PBS , then centrifuged at 163,700 x g for 120 min.  The 
virus-containing fractions were harvested. PBS was added to the virus to dilute the 
iodixanol.  The diluted solution was centrifuged (72,000 x g for 5 h) to pellet the virus 
and remove the iodixanol.  The virus pellet was resuspended in PBS and protein content 
was estimated by spectrometry. The virus was stored at -80°C.   
 
Immunization of mice. 
UV-inactivated purified DENV3 antigen was used to immunize mice. 
Immunization and cloning of hybridomas were conducted in the Immunology Core 
Faculty at the University of Alabama, at Birmingham. BALB/c mice were immunized 
with 10 µg of UV-inactivated virus in complete Freund's adjuvant.  About 24 days later, 
mice were boosted with 10 µg of UV inactivated virus in incomplete Freund's adjuvant.  
Mice were bled at 10-14 days post boost and the sera were tested for anti DENV 
antibodies.  Six weeks after the second boost in incomplete Freund's adjuvant, the mice 
received an intravenous (IV) injection of 10 µg of virus in saline.  Three days after the IV 
boost, splenocytes from immunized mice were fused using PEG and the P3X63-Ag8.653 
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myeloma line.  The fusied cells were plated into 24 well plates in Hypoxanthine 
Aminopterin Thymidine (HAT) medium and supernatants were tested for anti-DENV 
antibodies, and positive hybridomas were cloned by limiting dilution using peritoneal 
macrophage feeders. 
 
Expression and purification of recombinant EDIII (rEDIII).  
RNA was extracted from the supernatants of cells infected with DENV3 strain 
CH53489 using QIAmp Viral RNA mini Kit (Qiagen).  The nucleotide sequences 
encoding EDIII of DENV3 (295- 398 AA) were reverse transcribed and PCR amplified.  
The PCR products were cloned into the pMAL c2X vector (NEB) to generate 
recombinant EDIII (MBP-EDIII) that is fused to maltose binding protein (MBP) at the N 
terminus according to the manufacture’s instructions. MBP-EDIII from DENV3 was 
expressed in Escherichia coli DH5α (Invitrogen) and purified using amylose resin 
affinity chromatography (NEB).   Purity of the rEDIII protein was confirmed on an SDS-
PAGE gel, and the protein quantity was measured spectrometrically. 
 
Detection of DENV-reactive antibody in immunized mouse sera and hybridoma 
culture supernatants by ELISA. 
Seventy five nanograms (75 ng) of purified DENV3 or 200 ng of MBP-EDIII 
were used to coat ELISA plates.  ELISA plates were coated using virus or recombinant 
protein antigen in carbonate buffer at pH 9.6 for 2 hrs at room temperature.  The plates 
were washed 3 times in Tris-buffered saline with 0.2% Tween20 (TBST) and incubated 
with blocking buffer (Tris-buffered saline with 0.05% Tween20 containing 3% skim milk 
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and 2% normal goat serum) at 37C for 1 hr.  After washing the plates twice with TBST, 
mouse immune serum or cell culture supernantant diluted in blocking buffer was added to 
each well and incubated at 37C for 1 hr.  Following 3 washes with TBST, alkaline 
phosphatase-conjugated goat antimouse IgG  (Sigma) was added to each well for 1 hour 
at 37C.  After 3 washes with TBST, p-nitrophenyl phosphate substrate (Sigma) was 
added to each well and the reaction was allowed to develop for 15 minutes before 
recording optical density at 405nm on a spectrophotometer.  
 
DENV Neutralization assays 
 
DENV neutralizing antibodies in immunized mouse sera or cell culture 
supernatants were measured using a flow cytometry-based neutralization assay which 
was  performed in 96-well plates with the U937 human monocytic cell line transfected 
with DC-SIGN as previously described [7].  In brief, mouse immune sera were serially 
diluted, and cell culture supernatants were used as undiluted or at 1:2 dilutions.  Cell 
culture supernatants or serially diluted mouse sera were incubated with sufficient virus 
(DENV3- strain CH 53489) to infect 10 to 15% of the cells in the well.  The virus/serum 
or cell culture mixture was incubated for 1hr at 37C and then added to the cells for 1hr at 
37C.  The cells were washed to remove unbound virus and fresh medium was added 
before incubating cells for 24hrs at 37C. Cells were fixed, permeabilized and stained with 
DENV mAb 2H2,  which binds to all four serotypes [7].  Cells were analyzed with a 
FACScan flow cytometer (Becton Dickinson) to identify infected cells.  The 50% 
neutralization titers were determined by nonlinear dose-response regression analysis 
((Prism Package, GraphPad Software, Inc., San Diego, CA).  Cell culture supernatants 
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which contained neutralizing mouse mAb were further tested for differential 
neutralization potential against all of the genotypes of DENV3.  The procedure was same 
as mentioned above, except for the use of equal genome copy numbers from each 
genotype and incubation times range from 36 hours to 72 hours to get infection of  10-
15% of cells. 
 
3.4 Results: 
Mice were immunized with purified, UV-inactivated whole virus as outlined in the 
Materials and Methods section.  After the initial immunization, each mouse was bled and 
tested for the presence of anti-DENV Ab against DENV3 and rEDIII antigens.  
Furthermore, before the fusion, sera were tested for the presence of neutralizing Abs, and 
the mouse which had the higher 50% neutralization titer against parental DENV3 was 
selected for fusion. 
 We noticed that some of the supernatants  collected from the wells after the 
fusion consisted of non-specific antibodies with strong affinity to the plastic.  Such 
supernatants or “plate binders” were not selected, irrespective of their neutralization 
abilities.  All the wells with non-plate binders were selected and further tested for their 
reactivity with purified DENV3 and rEDIII antigens as well as neutralization of the 
parental virus strain CH53489.  Any supernatant that neutralized parental DENV3 was 
further tested for differential neutralization of DENV3 genotypes.  Twenty seven mAbs 
were selected for further subcloning, purification and characterization such as 
neutralization and binding to virus or rEDIII ( table 3.1). 
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One major goal of developing mouse mAb against DENV3 was to isolate EDIII- 
reactive antibodies.  Therefore, the initial attempts were focused on such antibodies, and 
this resulted in the identification of four EDIII-reactive mAbs.  Two of these mAbs were 
used in experiments described in chapters 4 and 5 of this thesis, and development and 
characterization of the other mAbs are in progress. 
 
3.5 Discussion: 
Mouse mAb against DENV3 were successfully  developed.  The panel of mAb 
varied from non- neutralizing antibodies to neutralizing mAb which bind to either virus 
or rEDIII or both (table 3.1).  Amino acid variability of the E protein among the members 
of DENV3 may be critical in determining the neutralization potential of a mAb.  Since 
the panel of mAbs developed contained rEDIII binding and non-rEDIII binding mAbs, 
those mAbs will be a useful tool to study the neutralization mechanisms of DENV3, 
including differential neutralization among the members of DENV3 genotypes.  In 
addition, it has been shown that EDIII-reactive antibodies play a minor role in type- 
specific neutralization after natural infection in human (chapter 5).  Thus, non-EDIII 
binding neutralizing mAb will be a useful tool to study the epitopes that are targeted by 
type-specific neutralizing antibodies in human sera using competitive binding assays. 
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 Table 3.1 Binding and neutralization properties of mouse mAb 
 ELISA was conducted with purified virus and  rEDIII protein. A   
 representative strain from each genotype of DENV3 was used in  
 neutralization assays. 
                
 
  
 
Chapter 4 
Natural Strain Variation and Antibody Neutralization of Dengue Serotype 3 Viruses 
 
   [WMPB Wahala, Eric F. Donaldson, Ruklanthi de Alwis, Ralph S. Baric and Aravinda M.      
   de Silva,  submitted for publication. 
   Design of rEDIII constructs, expression and purification of rEDIII protein, purification of    
   virus, design of  experiments, initial sequence analysis to identify the amino acid difference   
  on EDIII lateral  ridge, and data analysis were conducted by WMPB Wahala.  Identification   
  of informative sites on EDI  EDII, and EDIII were done by Eric F. Donaldson  and Ralph S.    
  Baric.  Ruklanthi de Alwis purified  mAbs 8A1 and 14A4.]  
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4.1 Abstract 
Dengue viruses (DENVs) are emerging, mosquito-borne flaviviruses which cause 
dengue fever and dengue hemorrhagic fever.  The DENV complex consists of 4 serotypes 
designated DENV1-DENV4. Following natural infection with DENV, individuals develop 
serotype-specific, neutralizing antibody responses.  Monoclonal antibodies (mAbs) have 
been used to map neutralizing epitopes on dengue and other flaviviruses.  Most serotype-
specific, neutralizing mAbs bind to the lateral ridge of domain III of E protein (EDIII).  It has 
been widely assumed that the EDIII lateral ridge epitope is conserved within each DENV 
serotype and a good target for vaccines. Using phylogenetic methods, we compared the 
amino acid sequence of 175 E proteins representing the different genotypes of DENV3 and 
identified a panel of surface-exposed amino acids, including residues in EDIII, that are 
highly variant across the four DENV3 genotypes.  The variable amino acids include six 
residues at the lateral ridge of EDIII.  We used a panel of DENV3 mouse mAbs to assess the 
functional significance of this naturally occurring amino acid variation.  From the panel of 
antibodies, we identified three neutralizing mAbs that bound to EDIII of DENV3.  
Recombinant proteins and naturally occurring variant viruses were used to map the binding 
sites of the three mAbs.  The three mAbs bound to overlapping but distinct epitopes on 
EDIII.  Our empirical studies clearly demonstrate that the antibody binding and 
neutralization capacity of two mAbs was strongly influenced by naturally occurring 
mutations in DENV3.  Our data further demonstrate that the lateral ridge “type specific” 
epitopes are not conserved between naturally occurring strains of DENV3.  This variability 
should be considered when designing and evaluating DENV vaccines, especially those 
targeting EDIII. 
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4.2 Introduction 
Dengue viruses (DENVs) are mosquito-borne flaviviruses and the agents of dengue 
fever and dengue hemorrhagic fever (DHF).  According to the World Health Organization, 
over 2.5 billion people are at risk of contracting dengue, 100 million people develop 
symptomatic infections and up to 50,000 die from DHF each year.  The DENV complex 
consists of 4 serotypes (DENV1-DENV4). DENVs have antibody epitopes that are unique to 
each serotype and epitopes that are cross-reactive between serotypes.  People who have 
recovered from primary DENV infections develop long term, protective immune responses 
against the homologous serotype only.  In fact, individuals exposed to a second infection with a 
different serotype face a greater risk of developing DHF, indicating that pre-existing immunity can 
exacerbate disease under some conditions [1].   
As previously infected individuals do not appear to be re-infected with the same 
serotype, it is widely assumed that neutralizing antibody epitopes are conserved among 
strains belonging to the same serotype [2,3].  In fact, the current strategy for developing 
dengue vaccines is based on the assumption that a neutralizing immune response directed to a 
single strain will protect against most if not all strains of DENV within the serotype.  
However, there is considerable genetic diversity within each serotype such that each has been 
subdivided into genotypes [4].  Despite this diversity, surprisingly few studies have explored 
how naturally occurring strain variation within each serotype influences DENV 
neutralization phenotypes.  In a study of pediatric dengue cases in Thailand, investigators 
observed significant differences in the ability of sera to neutralize reference and clinical 
strains of DENV3 [5].   Guzman and colleagues reported that amino acid sequence 
differences between DENV3 strains can have strong influences on virus neutralization by 
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murine and human immune sera [6].  Studies with other flaviviruses have also demonstrated 
that neutralization is dependent on the lineages and strains used in the assay [7,8].  Thus, the 
current paradigm may not accurately depict the complexity of DENV antigenic relationships, 
especially in DENV3. 
Antibodies, in particular, have emerged as key effector molecules responsible for 
protective and pathogenic immune responses to DENV [1].  The DENV envelope (E) protein 
is the major target of neutralizing antibody [9].  E protein mediates attachment to host cells 
and low pH fusion of the viral and host cell membranes.  The crystal structures of E from 
several flaviviruses (Tick borne encephalitis, DENV2, DENV3 and West Nile) have been 
solved [10-13].  Individual subunits of E protein consist of three beta-barrel domains 
designated domains I (EDI), II (EDII) and III (EDIII) and the native protein is a homodimer 
[10,11,13].  Mouse monoclonal antibodies (mAbs) that bind to all three domains of DENV E 
have been generated and characterized [9,14,15].  The most potent neutralizing mAbs bind to 
an epitope on the lateral ridge of EDIII of flaviviruses [9,16,17].  This epitope, which is not 
conserved between dengue serotypes, has been the focus of much recent work because it 
might be the target of the natural human immune response that leads to type-specific 
neutralization.  Investigators are also testing EDIII as a vaccine for inducing antibodies that 
neutralize a specific serotype, without inducing serotype cross-reactive antibodies with 
potential for disease enhancement [18,19]. 
In the present study, we have examined the evolution and phylogenetic relatedness of 
the E protein sequences from a large number of viruses representing the different genotypes 
of DENV3.  These data reveal a complex evolutionary pattern that is not characterized by a 
sequential progression of changes over time as has been described for influenza and 
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noroviruses [20,21].  Rather, many surface exposed amino acids were variable between 
established genotypes of DENV3.  Especially noteworthy was the observation that the EDIII 
lateral ridge, which is a known site targeted by neutralizing mAbs in related flaviviruses, was 
variable between DENV3 genotypes.  We experimentally demonstrate that naturally 
occurring amino acid differences in DENV3 EDIII lead to differential binding and 
neutralization by mAbs.   
 
4.3 Materials and Methods  
Cells and Viruses: 
Aedes albopictus C6/36 cells were maintained at 28C in DMEM supplemented with 
10% FBS, penicillin, streptomycin in the presence of 5% CO2.  Human leukemic monocyte 
lymphoma cell line U937 expressing DC-SIGN (U937 DC-SIGN) were maintained at 37C in 
RPMI supplemented with 10% FBS, penicillin, streptomycin and 50 mM of beta 
mercaptoethanol in the presence of 5% CO2.  DENVs were grown in C6/36 cells in DMEM 
supplemented with 02% FBS, penicillin, streptomycin in the presence of 5% CO2.  Virus 
strains used in the study were West Pacific 74 (DENV 1), S16803 (DENV2), UNC 3043 
(DENV3 -genotype I), CH53489 (DENV3 - genotype II), UNC 3009 (DENV3 - genotype 
III), PR77- 1342 (DENV3 -genotype IV), and TVP-360 (DENV4). 
 
Monoclonal Antibodies 
mAbs 8A1 and 14A4 against DENV3 were provided by Robert Putnak (Walter Reed 
Army Institute, MD).  mAb1H9 was provided by John Aaskov (Queensland University of 
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Technology, Australia) [22].  mAbs 8A5 and 12C1 were generated for this study by 
immunizing mice with purified DENV3 strain CH53489.  
 
Expression and purification of recombinant EDIII (rEDIII) 
Envelope gene fragments encoding EDIII from DENV1, DENV3, and DENV 4 
(AA295-398) and DENV2 (AA297-399) were amplified using Vent polymerase (NEB, 
Ipswich, MA).  Reverse primers used in the study were designed to introduce either a HindIII 
(for DENV2-4) or PstI (for DENV1) restriction site at the 3’ ends of the PCR products. PCR 
products were digested with HindIII or PstI and cloned into pMAl C2X (NEB, Ipswich, MA) 
vector using DH5a competent cells to generate fusion proteins of rEDIII and maltose binding 
protein (MBP). Recombinant EDIII was expressed and purified using an amylose resin 
(NEB, Ipswich, MA) and following the manufacture’s instructions. 
 
Mutagenesis of recombinant EDIII (rEDIII) 
Primers were designed using QuikChange® Primer Design Program 
(www.stratagene.com) and selected amino acids residues on rEDIII  were mutated by site 
directed mutagenesis using Quickchange multi kit (Stratagene, La Jolla, CA) according to 
manufacturer’s instructions.  Mutated single stranded pMal c2X plasmids (NEB, Ipswich, 
MA) were cloned into DH5α cells for expression and purification of mutant rEDIIIs.  All 
mutants were confirmed by sequencing. 
Binding ELISA with rEDIII protein 
ELISA plates were coated with 200ng of purified EDIII-MBP protein in Carbonate 
buffer overnight at 4C. An antibody that binds to MBP (NEB, Ipswich, MA) was used to 
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confirm equal binding of recombinant EDIII proteins to the ELISA plate.   The plates were 
washed and blocked with 3% normal goat serum (NGS) in Tris-buffered saline with 0.1% 
Tween 20 (TBST) for an hour at 37C.  Serially diluted mAbs in (blocking buffer) were then 
added to each well and incubated for one hour at 37C.  After washing 3 times with TBST, 
alkaline phosphatase conjugated goat anti-mouse antibody was added to each well and 
incubated for one hour at 37C.  Plates were washed three times with TBST, and color was 
developed by adding SIGMA FAST p-Nitrophenyl Phosphate tablets.  Optical density (OD) 
was measured at 405 nm using a spectrophotometer. 
 
Neutralization assays 
The neutralization protocol as described by Krause, et. al., was used with 
modifications to determine 50% neutralization values for each antibody [23].  In experiments 
comparing different genotypes of DENV3, the same amount of virus (genome copies) was 
used to infect cells with each genotype.  Different concentrations of mAbs were mixed with 
virus strains in a 96 well tissue culture plate and maintained at 37C in CO2 incubator for one 
hour. After the incubation, U937DC-SIGN cells were added to each well and maintained for 
an additional 2 hr for adsorption of virus. The cells were then washed with medium, and 200 
ul of fresh media were added to each well and incubated for 24-72 hr at 37C under 5% CO2.  
After washing 2 times with PBS, the cells were permeabilized and fixed using CytoFix/ 
Cytoperm kit (BD bioscience).  The cells were then stained with Alexa 488 conjugated anti- 
dengue mAb 2H2, and the percentage of infected cells was measured in a flowcytometer.   
EC50 values were calculated using GraphPad Prism version 4.00 for Windows (GraphPad 
Software, San Diego California USA, www.graphpad.com) and nonliner regression analysis. 
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DENV3 Sequence Analysis  
A total of 175 unique DENV3 full-length envelope protein sequences were 
downloaded from GenBank and these were aligned using ClustalX version 1.83 [24] using 
the PAM distance matrix and default parameters.  A variety of parameters and substitution 
matrices for the alignment were evaluated using the program TuneClustalv1.0 
(http://www.homepage.mac.com/barryghall/Software.html), and the PAM series matrix was 
determined to be the most appropriate, with default gap opening and extension values.  The 
alignment was refined manually, and 47 sites of variation, defined as any site with a quality 
score of less than 100, were exported in table format and ordered by genotype and domain.  
A representative subset of sequences was selected to represent specific DENV3 genotypes, 
and these contained 32 informative sites.  Informative sites were defined as columns of 
heterogeneity in the alignment where the same amino acid change occurred in at least three 
independent sequences.  
 
4.4 Results 
Variable Amino acids in the DENV3 E protein 
As individuals infected with DENV develop a long term, protective immune response 
to the homologous serotype, it has been assumed that neutralizing antibody epitopes are 
conserved within each serotype [9,25].  To further evaluate this assumption, we used 
phylogenetic approaches to compare the evolution of the full length E protein sequence of 
175 DENV3 strains.  The sequences, which were obtained from Genbank, were shown to 
contain representatives of each of the 4 recognized genotypes of DENV3 [26].  Informative 
sites were defined as positions that were variable in 3 or more independent sequences as 
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identified by alignment.  Of the 493 amino acids encoding the DENV3 E protein, 32 sites 
encoded informative mutations (Figure 4.1).  Individual subunits of E protein consist of three 
beta-barrel domains designated domains I (EDI), II (EDII) and III (EDIII) (Figure 4.2A).  
Informative sites were present in all domains of the E protein (Figure 4.1).  Many of the 
informative sites had mutations that were conserved within but not between DENV3 
genotypes (Figure 4.1).  As the structure of the ectodomain (AA 1 to 392) of DENV3 E 
protein has been solved, we were able to determine if the variable sites were either surface 
exposed or buried [11].  Eighteen of 28 sites in the ectodomain were surface exposed, while 
others were partially or completely buried in the molecule (Figure 4.1).   
 
Relationship of DENV3 E protein informative sites to known antibody epitopes 
We compared the locations of known antibody epitopes on the flavivirus E protein 
and the positions of informative sites on DENV3 E protein.  Mouse monoclonal antibodies 
(mAbs) that bind to EDI and II have been mapped to six regions (Figure 4.2A and Table 4.1) 
[9,16].  Most of the informative sites were within or adjacent to these antigenic regions 
(Figure 4.2A and Table 4.1).  However, the antigenic region at the fusion loop was 
completely conserved between DENV3 strains (Table 4.1).     
Many mouse mAbs that strongly neutralize flaviviruses bind to EDIII.  DENV 
serotype-specific (type-specific), neutralizing mAbs bind to epitopes on the lateral ridge of 
EDIII, which is formed by three loops connecting the D-E, B-C, F-G beta strands on EDIII 
and the linker region connecting EDIII and EDI (Figure 4.2B and Table 4.1) [9,16]. 
Investigators have also defined an epitope on EDIII recognized by mAbs that neutralize more 
than one DENV serotype [14,27,28].  This DENV subcomplex epitope overlaps with the 
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lateral ridge epitope but is centered at positions 305-308 (DENV3 numbering) on the A 
strand of EDIII (Figure 4.2B and Table 4.1).  We compared the positions of known antibody 
epitopes and DENV3 informative sites on EDIII.  The dengue type specific, lateral ridge 
epitope overlapped extensively with the informative sites on EDIII (Figure 4.2B, Table 4.1).  
This analysis supports the hypothesis that the EDIII lateral ridge epitope engaged by strongly 
neutralizing mouse mAbs is not conserved between DENV3 strains. 
 
Mapping of DENV3, EDIII reactive antibodies 
To directly address whether natural amino acid variation in DENV3 EDIII results in 
altered antibody binding and neutralization, we assembled and mapped a panel of DENV3 
EDIII reactive mouse mAbs.  The sources and general properties of mAbs used in the current 
study are listed in Table 4.2.  All 5 antibodies selected for this study (8A1, 1H9, 14A4, 8A5, 
and 12C1) bound to EDIII of DENV3 (Figure 4.3).  8A1 and 1H9 were type specific and 
only bound to DENV3, EDIII.  14A4 was sub-complex specific and bound to DENV3 and 
DENV1 (Figure 4.3).  3B12 and 12C1 cross reacted with EDIII from all 4 serotypes (Figure 
4.3).    
To map the binding sites of the mAbs, we expressed and purified 28 EDIII 
recombinant proteins with defined mutations, primarily in the lateral ridge loops. The binding 
of each antibody to wild type and mutant proteins was compared by ELISA (Table 4.3).  
mAb 1H9 is a type specific, neutralizingDENV3, EDIII reactive IgM antibody that has 
previously been shown to select for escape mutation at position 386 [22].  We observed a 
greater than 80% loss of binding of 1H9 when amino acids at positions 302,304,308,310 323, 
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325-330, 357, 358, 361, 380, 382 or 386 were mutated on EDIII (Table 4.3).  Most of these 
mutations are on the lateral ridge of EDIII (Figure 4.4).  
mAb 8A1 is a strongly neutralizing, type-specific DENV3, EDIII-reactive IgG 
antibody.  With this antibody, we observed a greater than 80% loss of binding when amino 
acids at positions 301, 302, 304, 326-328, 330, 361, 380, 382 or 386 were mutated on EDIII 
(Table 4.3).  As in the case of 1H9, most of these positions overlap with the EDIII lateral 
ridge epitope.  However, 1H9 and 8A1 did not bind to identical epitopes because some 
mutations that influenced 1H9 had marginal to no effect on 8A1.   
mAb 14A4 is a neutralizing EDIII reactive IgG antibody that cross-reacts with 
DENV3 and DENV1 (Figure 4.3).  This DENV subcomplex antibody bound poorly to 
recombinant proteins with mutations at position 308 (A strand), or positions 326 or 328 (B-C 
loop) (Table 4.3).  These mutations are located at a similar position to a DENV EDIII sub- 
complex epitope recently described in the literature [14,27].  The subcomplex epitope 
overlaps with the lateral ridge but is centered on the A strand of EDIII.   
The DENV complex cross-reactive mAbs (8A5, 12C1) bound to all the mutant 
proteins indicating these antibodies likely bind to a cross-reactive epitope outside the lateral 
ridge region (Table 4.3).  In Figure 4.4 we display the structure of DENV3 EDIII and the 
location of mutations that reduced the binding (>80%) of each mAb. 
 
Binding of mAbs to different genotypes of DENV3  
Several amino acid positions (301, 302, 329, 380 and 386) on EDIII implicated in 
binding to mAbs 8A1 and 1H9 (Table 4.3) were also identified as informative sites that were 
not conserved between DENV3 genotypes (Figure 4.1).  All these positions are located in 
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close proximity to one another on the EDIII lateral ridge.  To directly address whether 
naturally occurring variation at these informative sites leads to altered antibody interactions, 
we compared the binding of mAbs 1H9, 8A1 and 14A4 to representative EDIII from each of 
the 4 distinct genotypes of DENV3.   mAbs 8A1 and 1H9 bound to genotypes I, II and III but 
not to EDIII from genotype IV (Figure 4.5).  The DENV subcomplex specific 14A4 antibody 
bound to EDIII from all 4 genotypes (Figure 4.5).  Studies were also performed to compare 
the binding of these mAbs to purified viruses (Figure 4.6).  As predicted from the 
recombinant EDIII binding experiments, 1H9 bound to DENV3 genotype I, II and III viruses 
but not to the genotype IV virus (Figure 4.6).  Similarly, mAb 8A1 bound to genotypes I, II, 
and III but not to the genotype IV (Figure 4.6).  mAb 14A4 bound to all 4 genotypes.  These 
results indicate that naturally occurring amino acid variation on DENV3 EDIII influence the 
binding of type-specific antibodies.  
 To verify that amino acid differences at the EDIII lateral ridge were responsible for 
mAb binding differences, further studies were conducted with mAb 8A1 and recombinant 
EDIII proteins.  We systematically changed amino acids in the EDIII genotype IV construct 
to genotype II and defined the minimum number of changes required to restore the 8A1 
epitope. In Figure 4.7 we depict the EDIII amino acid differences between the different 
genotypes.  Simply making single amino acids changes at positions 301 or 302 did not 
restore binding.   Some binding was regained when both 301 and 302 were changed from SG 
(genotype IV) to LN (genotype II) (Figure 4.7). Full binding was restored when positions 
301, 302 and 380 were changed (Figure 4.7) indicating that these were the critical changes 
that led to the loss of binding of mAb 8A1 to DENV3 genotype IV.   Residues 301, 302 and 
380 are surface-exposed neighbors on the lateral ridge of EDIII, with residues 301 and 380 
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separated by approximately 4.7 Angstroms.  Thus, these three residues are likely to be a part 
of a single epitope bound by 8A1. 
 
Neutralization of DENV3 genotypes by MAbs 
Experiments were conducted to compare the ability of EDIII mAbs to neutralize 
different genotypes of DENV3.  mAbs 8A1 and 1H9 failed to neutralize DENV3 genotype 
IV, which was expected since these antibodies did not bind to this virus (Table 4.4).  
Surprisingly, even though we did not observe differences in the binding of 8A1 and 1H9 to 
genotype I, II and III viruses, we did observe differences in the neutralization titer  (Table 
4.4).  For example the neutralization titers for 8A1 arranged nearly 10 fold between genotype 
I and III viruses (Table 4.4).  1H9 displayed a 60 fold difference in the neutralization titer 
between genotype I and II viruses (Table 4.4).  These results indicate that two mechanisms 
influence the ability of mAbs to neutralize virus infectivity.  In the first, mutations which 
ablate binding also ablate neutralization.  In the second, genetic differences between DENV3 
strains that have little effect on apparent affinity can have significant biological effects on 
neutralization. 
 
4.5 Discussion   
A long-held paradigm in flavivirus research has been that DENVs display little if any 
intra-serotypic antigenic variation, and this has been the basis for the development of current 
multivalent vaccines and immunotherapeutics [9,16].  The main goal of the current study was 
to characterize the extent of envelope protein variation within the DENV3 serotype and to 
determine if this variation influenced antibody binding and neutralization.  Sequence and 
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structural analysis of the E protein indicated that 7% of the amino acids were variable 
between the four genotypes of DENV3, and most of the non-conserved residues were surface 
exposed and located at or proximal to known antibody binding sites.  Particularly striking 
was the variation observed on the lateral ridge of domain III, which has previously been 
identified as the target of antibodies that strongly neutralize flaviviruses [9,16].  Finally, we 
demonstrated that natural variation in EDIII influences the ability of mAbs to bind and 
neutralize DENV3. 
Studies with other flaviviruses have demonstrated that neutralization is dependent on 
the lineage and strain of these viruses [7,8].  Recent studies indicate that strain variation 
influences the neutralization of DENV3 as well.  In a study with Thai subjects, Endy and 
colleagues observed differences in the ability of human immune sera to neutralize different 
strains of DENV3 [5].  Guzman and colleagues reported that amino acid differences in EDIII 
were responsible for poor binding and neutralization of some DENV3 strains compared to 
others [6].  Our results reported here, together with the other studies mentioned above, 
challenge the long held view that neutralizing antibody epitopes are conserved across DENV 
strains belonging to the same serotype.   
Dengue virus evolution is complex, and, to date, there is little evidence of herd 
immunity driving the selection of novel strains [29].  Studies have demonstrated that 
individuals exposed to a secondary infection with a different serotype have a higher serum 
viremia and face a greater risk of developing DHF.  A leading theory to explain the more 
severe nature of secondary dengue is that serotype cross reactive, non-neutralizing antibodies 
from the first infection enhance the ability of the virus to infect Fc-receptor bearing host 
cells, which initiates a cascade of events that lead to DHF [25].  Our results reported here 
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indicate that the different genotypes of DENV3 encode variable antibody epitopes on the 
surface of the viral envelope protein.  Studies are needed to address how antigenic 
differences within a serotype might alter the ability of human antibodies to enhance DENV 
as well.  Although speculative, complex pre-exposure histories may select for specific 
genotypes or strains of DENV that are poorly neutralized and/or preferentially enhanced by 
pre-existing immunity. 
Our results show that EDIII lateral ridge antibodies 8A1 and 1H9 bound to DENV3 
genotypes I, II and III but not genotype IV indicating that naturally occurring mutations in 
EDIII can lead to a total loss of mAb binding.  Even though mAbs 8A1 and 1H9 bound to 
DENV3 genotypes I, II and III with similar apparent affinity measured by ELISA, we 
observed striking differences in the ability of the mAbs to neutralize these viruses.  The 
neutralization titers were almost 10 fold different between viruses for 8A1 and nearly 60 fold 
different for 1H9.  The small differences in Kd values (fig 4.6) among the genotypes of 
DENV3 did not correlate with the rank order of neutralization (table 4.4).  Our results 
indicate that apparent affinity of antibody to virus immobilized on ELISA wells is not always 
predictive of the neutralization titer.  There are amino acid differences on the EDIII lateral 
ridge of genotype I, II and III viruses (Figure 7.7), and these changes may lead to subtle 
changes in virus antibody interactions that are not detected in our solid phase binding assay.  
As viral binding and entry are accompanied by overall changes in the conformation of E 
protein from a dimer to a trimer, even mutations distal to EDIII might influence the ability of 
antibodies to bind the lateral ridge and neutralize DENV3.  Other investigators have also 
documented that apparent affinity is not always correlated with the neutralization strength of 
antibodies against viruses, including flaviviruses [30-32].    Further studies are needed to 
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dissect the mechanism underpinning the ability of EDIII lateral ridge antibodies to neutralize 
different genotypes of DENV3. 
Studies with DENV2 have demonstrated the presence of antibody epitopes on the 
lateral ridge, A strand and AB loop.  The lateral ridge and A strand epitopes are recognized 
by type-specific and cross-reactive neutralizing mAbs respectively, whereas the AB loop 
epitope is the target of weakly or non-neutralizing mAbs [14].  Our results demonstrate a 
similar distribution of epitopes on DENV3.  mAbs 1H9 and 8A1 define a type specific 
epitope on the lateral ridge of DENV3, EDIII.  mAb 14A4 recognizes a dengue sub-complex 
epitope centered on the A strand.  Others have also described a dengue complex or sub- 
complex epitope centered on the A strand of DENV3 [33].  None of the mutations we made 
in and around the lateral ridge region influenced the binding of mAbs 8A5 and 12C1, which 
were serotype cross-reactive, non-neutralizing antibodies.  We suspect these antibodies bind 
to a recently described epitope on the A-B loop that is poorly exposed on the virion and the 
target of other weakly or non-neutralizing antibodies [14].  Thus, the EDIII epitope landscape 
of DENV3 may well be similar to DENV2, consisting of type-specific and cross-reactive 
epitopes. 
The experiments reported here focused on antibodies that bind to EDIII.  Our DENV3 
sequence analysis indicates that many antigenic regions in EDI and EDII are also poorly 
conserved across DENV3 strains.  Further studies are needed to identify key epitopes in EDI 
and EDII and to evaluate their conservation both within and between serotypes.  While this 
work focused on DENV3, our results suggest that intraserotype strain variation might also 
influence the neutralization of other serotypes.  Kochel and colleagues reported that the 
American genotype of DENV2 was more sensitive than the Asian strain of DENV2 to cross- 
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neutralization by DENV1 immune sera [34].  Further studies are needed to characterize the 
extent of intraserotype variability and the neutralization characteristics of DENV1, 2 and 4, 
as well. 
In summary, our results indicate that the EDIII lateral ridge epitope targeted by 
strongly neutralizing antibodies is not conserved between the different genotypes of DENV3. 
Recently we discovered that people exposed to natural DENV infections have low levels of 
EDIII reactive antibody and that antibodies that bind to epitopes outside EDIII were most 
likely responsible for the neutralizing activity in human immune sera (chapter 5).  Thus, not 
only is EDIII variable between strains, but natural human infection does not induce high 
levels of antibody to this domain.  Antibody epitopes in EDI and II are likely to play a more 
important role in the neutralizing human antibody response to DENV.   
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Table 4.2. Source of mouse mAb used in the current study 
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  Mouse mAb   
Mutation 1H9 8A1 14A4 8A5 12C1 
I301A 97 13 100 100 99 
I301G 52 3 97 100 100 
N302A 9 4 95 100 99 
N302G 223 12 100 98 99 
T303A 107 77 100 100 100 
T303G 43 42 100 100 98 
F304A 15 5 30 90 100 
K308A 16 37 5 100 96 
V310A 16 54 83 97 100 
E323G 17 69 99 100 95 
K325A 57 74 38 99 98 
K325G 12 25 80 90 100 
G326A 10 5 18 96 97 
E327A 13 4 72 98 100 
D328A 10 4 5 93 100 
A329G 11 28 74 100 96 
P330A 11 6 29 95 100 
T357A 35 76 100 97 98 
T357G 13 47 100 99 97 
K358G 17 50 100 95 100 
E361G 6 10 100 98 100 
I380A 18 5 97 98 96 
I380G 4 4 88 96 98 
D382G 5 15 90 98 95 
K383A 106 92 100 100 99 
K383G 101 97 99 99 100 
K386A 4 35 97 96 98 
K386G 4 15 96 98 100 
 
                               1 Binding to each mutant expressed as a percentage of binding to  
                       wild type EDIII protein from genotype II 
                              2 The values in bold indicate mutations that reduced mAb biding 
                       by >80% compared to the wild type EDIII 
 
                Table 4.3. Binding of mouse mAbs to mutant DENV3 EDIII proteins 
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 50% Neutralization titer1 (µg/ml ± std error of mean) 
  DENV3 genotype  
mAb I II III IV 
8A1 0.43 ± 0.15 1.3 ± 0.32 4.4 ± 0.67          NN2 
1H9 0.02 ± 0.002 1.2 ± 0.69 0.37 ± 0.02          NN 
14A4 0.64 ± 0.34 1.8 ± 0.54 2.2 ± 0.18 0.25 ± 0.02 
 
                                1 50% neutralization titer determined using U937+DC-SIGN expressing cells 
                                2 Not neutralized 
 
                 Table 4.4 . Neutralization of DENV3 genotypes by EDIII mAbs 
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Figure 4.2. Location of mAb epitopes and informative sites on DENV3 E protein.  The 
figure is based on the structure of the ectodomain of DENV3 E protein solved by Modis and 
colleagues.  A.  The flavivirus E protein consist of three beta-barrel domains designated 
domains I (red), II (yellow) and III (blue). The native protein is a homodimer that lies flat on 
the surface of the virus. The top image depicts the major antigenic sites on domains I and II 
(see Figure 4.1 for details).  The bottom image displays the location of informative sites on 
domains I and II (pink).  B.  An enlarged view of domain III displaying antigenic sites and 
informative sites.  The left image displays the lateral ridge and A strand epitopes.  The right 
image displays the domain III informative sites (pink).
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Figure 4.3.  Binding of mouse mAbs to recombinant EDIII from the 4 serotypes of 
DENV.  mAb binding was detected by ELISA. mAbs 8A1 and 1H9 bound to EDIII from 
DENV3 only.  m14A4 bound to EDIII from DENV3 and to a lesser extent to EDIIII from 
DENV1. mAbs 8A5 and 12C1 bound to EDIII from all 4 serotypes. 
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Figure 4.4.  Mapping EDIII epitopes for mAbs 8A1, 1H9 and 14A4.  The figure depicts 
the positions of mutations that reduced mAb binding by >80%.  Many mutations mainly on 
the lateral ridge reduced binding of 8A1 and 1H9. In contrast only three mutations inhibited 
binding of 14A4.  
8A1 1H9 14A4
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Figure 4.5.  Binding of mouse mAbs to recombinant EDIII from the 4 genotypes of 
DENV3.  mAb binding was detected by ELISA. mAbs 8A1 and 1H9 bound to EDIII from 
DENV3 genotypes I, II and III but not to IV.  mAbs 14A4, 8A5 and 12C1 bound to all 4 
genotypes.  
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Figure 4.6. Binding of mouse mAbs to DENV3 genotypes.  DENV3 genotype I (DV3-I), 
genotype II (DV3-II), genotype III (DV3-III) and genotype IV (DV3-IV) viruses were 
purified and used in binding assays with mAb 8A1, 14A4 and 1H9. mAb 14A4 bound to all 4 
genotypes with similar apparent affinity.  mAbs 8A1 and 1H9 bound to DENV3, genotypes I, 
II and III with similar apparent affinity, while no binding was detected with genotype IV 
virus. 
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Figure 4.7. Identification of naturally occurring mutations that eliminate binding of 
mAb 8A1.  The table displays the EDIII amino acid differences between the different 
genotypes of DENV3.  mAb 8A1 bound to EDIII from DENV3 genotype II (DV3-II) but not 
genotype IV (DV3-IV).  Binding was partially restored when positions 301 and 302 were 
changed from the genotype IV to genotype II (DV3-IV SG301-2LN)).  Complete binding 
was restored when positions 301, 302 and 380 were changed (DV3-IV SG301-2LN, T380I. 
 
 
  
 
CHAPTER 5 
Dengue virus neutralization by human immune sera: role of envelope protein domain 
III - reactive antibody 
 
[W.M.P.B. Wahala, Annette A. Kraus, Laura B. Haymore, Mary Ann Accavitti-Loper and 
Aravinda M. de Silva. Virology (2009), doi:10.1016/j.virol.2009.06.037 
Design of rEDIII constructs, expression and purification of rEDIII proteins, design and 
conducting of experiments, data analysis, were done by WMPB Wahala. Kraus AA and 
Haymore LB collected blood from human subjects used in the study and conducted initial 
characterization of sera to determine the neutralization titer of each serum sample. Accavitti-
Loper  MA developed mouse mAb 12C1 and 8A5 in collaboration with WMPB  Wahala.] 
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5.1 Abstract 
Dengue viruses (DENV) are the etiological agents of dengue fever (DF) and dengue 
hemorrhagic fever (DHF).  The DENV complex consists of four closely related viruses 
designated DENV serotypes 1 through-4.  Although infection with one serotype induces 
cross-reactive antibody to all 4 serotypes, the long term protective antibody response is 
restricted to the serotype responsible for infection.  Cross-reactive antibodies appear to 
enhance infection during a second infection with a different serotype.  The goal of the present 
study was to characterize the binding specificity and functional properties of human DENV 
immune sera.   The study focused on domain III of the viral envelope protein (EDIII), as this 
region has a well characterized epitope that is recognized by strongly neutralizing serotype-
specific mouse monoclonal antibodies (mAbs).  Our results demonstrate that EDIII-reactive 
antibodies are present in primary and secondary DENV immune human sera.  Human 
antibodies bound to a serotype- specific epitope on EDIII after primary infection and a 
serotype cross- reactive epitope on EDIII after secondary infection.  However, EDIII-binding 
antibodies constituted only a small fraction of the total antibody in immune sera binding to 
DENV.  Studies with complete and EDIII antibody-depleted human immune sera 
demonstrated that EDIII binding antibodies play a minor role in DENV neutralization.  We 
propose that human antibodies directed to other epitopes on the virus are primarily 
responsible for DENV neutralization.  Our results have implications for understanding 
protective immunity following natural DENV infection and for evaluating DENV vaccines. 
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5.2 Introduction 
Dengue viruses (DENVs) are emerging, mosquito-borne flaviviruses and the 
causative agents of dengue fever (DF) and dengue hemorrhagic fever (DHF).  The DENV 
complex consists of four serotypes designated DENV 1 through 4.  A person infected with 
DENV develops antibodies that cross react with all four serotypes [1].  However, the 
antibodies only provide long-term protection against the serotype responsible for the original 
infection and people can be infected a second time with a different serotype [2,3].  
Individuals experiencing secondary DEN infections face a greater risk of developing severe 
disease [2,3].  A leading theory to explain the greater risk of severe disease with secondary 
DEN infection is that pre-existing cross reactive antibodies bind to the virus and enhance 
infection of Fc-receptor bearing cells [4].  Despite the fact that DEN vaccines are entering 
large scale clinical testing, we know remarkably little about the relationship between the 
binding properties of DEN antibodies in human immune sera and the functional outcome of 
these interactions.   
The major target of flavivirus neutralizing antibody is the Envelope (E) protein, 
although membrane protein (M) and non-structural protein 1 (NS1) antibodies have also been 
shown to be protective [1,5,6].  E protein is responsible for viral attachment to host cells and 
the low pH fusion of viral and host cell membranes.  The crystal structures of E of several 
flaviviruses have been solved [7-10]. Individual subunits of E consist of three beta-barrel 
domains designated E domains I (EDI), II (EDII) and III (EDIII).  Native E is a homodimer 
that lies flat on the surface of the viral membrane.  
Our current understanding of the interactions between DENV and antibody is largely 
based on studies with mouse monoclonal antibodies (mAbs).  DENV neutralizing mouse 
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mAbs have been mapped to all three domains of E. In general, strongly neutralizing mouse 
mabs are DENV serotype-specific and bind to an epitopes on EDIII that is unique to each 
serotype [11-16].  A DENV type-specific epitope on EDIII bound by strongly neutralizing 
mabs has been mapped to 4 loops on the lateral face of EDIII [12,16,17].  Investigators have 
also mapped flavivirus cross reactive epitopes on EDIII [16,17].  Unlike DENV type-specific 
mAbs, cross-reactive mAbs that bind to EDIII have moderate to weak neutralizing activity. 
Despite the large body of work with mouse mAbs, remarkably little work has been 
done to characterize the binding properties of human DENV immune sera and to understand 
the relationship between human antibody binding and neutralization.  Convalescent sera from 
people and horses naturally infected with West Nile virus (WNV), a related flavivirus, had 
low levels of EDIII-reactive antibody [18,19].  In WNV immune sera, EDIII-binding 
antibodies were not primarily responsible for neutralization activity [18,19].  People who 
have recovered from DENV infections also develop EDIII-reactive antibodies [20-24]; 
however, most human antibody appears to be directed towards a flavivirus-cross reactive 
epitope close to the fusion loop in EDII of DENV [24,25].  To date, no studies have been 
done to directly test if EDIII-reactive antibodies are primarily responsible for the neutralizing 
activity of human DENV immune sera.  The goal of this study was to measure the level and 
specificity of EDIII-reactive antibodies in people who have recovered from primary and 
secondary DENV infections and to determine the contribution of EDIII-reactive antibodies to 
DENV neutralization. 
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5.3 Materials and Methods 
Viruses 
DENV1 WestPac-74, DENV2 S-16803, DENV3 CH-53489, and DENV4 TVP-360, 
provided by Dr. Robert Putnak (Walter Reed Army Institute of Research, Silver Spring, MD) 
were used in this study. . Working virus stocks were obtained by inoculating C6/36 mosquito 
cells in tissue culture flasks and growing the virus for eight days at 28°C. Supernatants were 
harvested, clarified at 2500rpm for 5min, supplemented with 15% FBS and stored in aliquots 
at -80°C. Viral titers were determined by plaque assay on Vero-81 cells as previously 
described [26]. 
 
Immune sera and Antibodies 
Convalescent DENV immune sera were obtained from volunteers who had 
experienced natural DENV infections during previous travel abroad.  The protocol for 
recruiting and collecting blood from people was approved by the Institutional Review Board 
of the University of North Carolina at Chapel Hill.  Sera from 6 DENV-immune subjects 
were used in the present study.  The properties of these sera are listed in Table 1.  We also 
used eight DENV-reactive mouse mAbs that bind to EDIII.  mAb 3H5-1 , obtained from 
Chemicon Co, CA, binds to EDIII of DENV2 only [12].  mAbs 8A1 and 14A4, which bind 
to EDIII of DENV3, were obtained from Dr. Robert Putnak (Walter Reed Army Institute of 
Research, Silver Spring, MD).  mAb 2Q1899 and 9F16 which bind to EDIII of DENV2 were 
obtained from United States Biological, Massachusetts. DENV3 EDIII reactive mAb 1H9 
was obtained from Dr John G Aaskov (Queensland University of Technology, Australia) 
[27].  DENV cross reactive EDIII mAb 8A5 and 12C1 were developed in collaboration with 
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the South Eastern Regional Center for Excellence in Biodefence monoclonal antibody core 
facility at the University of Alabama School at Birmingham.  
 
Purification of DENV antigen for ELISA 
DENV2 S-16803 and 3 CH53489 reference strains were grown in Vero-81 cells 
(ATCC CCL-81) at 37°C.   The virus containing media was harvested 5-7 days after infection 
and centrifuged to pellet cell debris.  The clarified media was laid on top of a 20% sucrose 
(wt/vol) cushion and centrifuged (72,000g for 5 hrs) to pellet the virus.  The virus pellet was 
allowed to dissolve overnight in PBS before layering on a 10%- 40% iodixanol gradient and 
being centrifuged at 163,700 x g for 120 min.  The virus-containing fractions were harvested. 
PBS was added to the virus to dilute the iodixanol.  The diluted solution was centrifuged 
(72,000 x g for 5 h) to pellets the virus and remove the iodixanol.  The virus pellet was 
resuspended in PBS and virus protein content was estimated by spectrometry. The virus was 
stored at -80°C.   
 
Expression of the ectodomain of E protein (Es) from DENV3 
RNA extracted from strain CH53489 of DENV3 was reverse transcribed and PCR 
amplified to generate a PCR product containing nucleotides coding for the last 15 amino 
acids of membrane protein and the first 415 amino acids of E protein followed by a 6 
histidine tag and a stop codon.  This construct was missing the C-terminal amino acids 
responsible for membrane anchoring of E protein.  The PCR product was cloned into pENTR 
TOPO vector (Invitrogen) and the BaculoDirect baculovirus Expression system (Invitrogen) 
was used to express recombinant protein according to manufacturer’s instructions.  Briefly, 
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the Es gene was recombined with BaculoDirect Liner DNA to generate recombinant 
baculovirus DNA.  pENTR/CAT plamsmid was used to produce recombinant baculovirus 
expressing the chloramphenicol acetyl transferase  (CAT) protein, which was later used as a 
negative control.  Sf9 insect cells were transfected with recombinant baculovirus DNA.  
P1,P2 and P3 recombinant virus stocks were generated according to the manufacturers 
instruction and expression of protein was confirmed  using western blot with mouse mAb 
4G2 ( for Es) or anti CAT antibodies. P3 baculovirus stocks were used to express Es and 
CAT proteins. 
 
Expression and purification of DENV EDIII 
RNA was extracted from supernatants of cells infected with DENV2 or 3 using 
QIAmp Viral RNA mini Kit (Qiagen).  The nucleotide sequences encoding for EDIII of 
DENV2 (297-399 AA) and DENV3 (295- 398 AA) were reverse transcribed and PCR 
amplified.  The PCR products were cloned into pMAL c2X vector (NEB) to generate 
recombinant EDIII (MBP-EDIII) that is fused to maltose binding protein (MBP) at the N 
terminus according to the manufacture’s instructions. MBP-EDIII from DENV2 and DENV3 
were expressed in Escherichia coli DH5α (Invitrogen) and purified using amylose resin 
affinity chromatography (NEB).    
 
Detection of dengue reactive antibody in human immune sera by ELISA 
ELISA plates were also coated with 75ng/ per well of purified DENV2 or 3 and the 
flavivirus cross reactive mAb 4G2 was used to confirm equal binding of each virus to the 
plate.  ELISA plates were coated with 200ng of MBP-EDIII from DENV2 or 3 per well.  
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Rabbit anti MBP sera (NEB) was used to confirm equal binding of MBP-EDIII from both 
serotypes to ELISA plates.  ELISA plates were coated using virus or recombinant protein 
antigen in carbonate buffer at pH 9.6 for 2 hrs at room temperature.  The plates were washed 
3 times in Tris-buffered saline with 0.2% Tween20 (TBST) and incubated with blocking 
buffer (Tris-buffered saline with 0.05% Tween20 containing 3% skim milk and 2% normal 
goat serum) at 37°C for 1 hr.  After washing the plates twice with TBST, human immune 
serum diluted in blocking buffer was added to each well and incubated at 37°C for 1 hr. 
Following 3 washes with TBST, alkaline phosphatase-conjugated goat antihuman IgG (Fc-
specific) (Sigma) was added to each well for 1 hour at 37°C.  After 3 washes with TBST, p-
nitrophenyl phosphate substrate (Sigma) was added to each well and the reaction was 
allowed to develop for 15 minutes before recording optical density at 405nm on a 
spectrophotometer. In ELISAs with mouse mAbs, the protocol was the same except that 
alkaline phosphatase-conjugated goat anti-mouse IgG was used as a secondary antibody.  To 
compare binding to DENV2 and DENV3 antigens, we normalized the data by using the 
serum sample # 24 (secondary dengue) that gave the highest OD with each antigen (DENV2, 
DENV3, DENV2 EDIII and DENV3 EDIII).  For each antigen the maximum OD obtained 
with serum #24 was defined as an OD of 1.  In figures 1 and 4 the Y axis is referred to as 
relative OD to indicate that the data was normalized using serum sample #24.   
As the Es antigen bound poorly to ELISA plates, we used an antigen capture method 
to compare the binding of whole virus and Es.  Plates were coated with 200ng of mAb 8A5 
in carbonated buffer at pH 9.6. This antibody binds to E protein from all 4 serotypes.  The 
antibody coated plates were washed and incubated with blocking buffer at 37°C for 1 hr. 
Next, sufficient DENV3 or Es antigen from DENV3 was added to saturate antigen binding to 
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the antibody coated plates.  CAT protein antigen was used as a negative control.  The plates 
were washed again before incubating with serial dilutions of dengue immune human sera.  
The rest of the assay was performed as described above for the direct antigen coating ELISA. 
 
Depletion of EDIII-reactive antibody in human immune sera 
Purified MBP-EDIII was dialyzed against 20 mM Tris-HCl, pH 7.4, 200 mM NaCl, 1 
mM EDTA (column buffer) overnight at 4°C.  MBP-EDIII (300 µg) was incubated with the 
amylose resin (NEB) in column buffer containing 3% normal human serum (NHS) and 
incubated overnight at 4°C.  The resin was washed three times with column buffer and 3 
more times with PBS to remove unbound MBP-EDIII.  The resin was blocked with 5% NHS 
in PBS before incubating with 1.5mls of human DENV immune serum diluted at 1:10 in PBS 
for 4 hrs at 37°C.  The amylose resin was pelleted and the EDIII antibody depleted human 
serum was collected.  Depletion of EDIII-reactive antibodies was confirmed by ELISA with 
MBP-EDIII.  In addition, each human immune serum sample was absorbed to an amylose 
resin with MBP alone.  MBP-absorbed immune sera and MBP-EDIII absorbed NHS were 
used as negative controls in subsequent neutralization assays 
 
DENV Neutralization assays 
DENV neutralizing antibodies was measured by plaque reduction neutralization test 
(PRNT) or a flow cytometry based neutralization assay.  The PRNT was performed as 
previously described [26].  In brief, Vero-81 cells were seeded into 24 well-plates and grown 
until 80% confluent.  Serially diluted sera were mixed with 30 plaque forming units (PFU) of 
virus and incubated for 1 hr at 37°C.  The virus/serum mix was added to the Vero cells and 
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incubated with a nutrient overlay medium (Opti-MEM® with 1% methylcellulose and 10% 
FBS) for four days at 37°C.  The cells were fixed and stained for viral antigen with 
monoclonal antibody 4G2 as previously described [26].  The percentage of neutralization 
was defined as reduction in the number of foci in the test sera compared to the number of foci 
in the control wells with normal human serum.  The 50% neutralization titers were 
determined by nonlinear dose-response regression analysis (Prism Package, GraphPad 
Software, Inc., San Diego, CA). 
Flow cytometry based neutralization assays were performed in 96-well plates with the 
U937 human monocytic cell line transfected with DC-SIGN as previously described [26].  In 
brief, immune sera were serially diluted and incubated with sufficient virus to infect 10 to 
15% of the cells in the well.  The virus/serum mixture was incubated for 1hr at 37°C and then 
added to the cells for 1hr at 37°C.  The cells were washed to remove unbound virus and fresh 
media was added before incubating cells for 24hrs at 37°C.  Cells were fixed, permeabilized 
and stained with DENV mAbs 4G2 or 2H2, both of which bind to all four serotypes [26]. 
Cells were analyzed with a FACScan flow cytometer (Becton Dickinson) to identify infected 
cells.  The 50% neutralization titers were determined by nonlinear dose-response regression 
analysis ((Prism Package, GraphPad Software, Inc., San Diego, CA). 
  
5.4 Results 
Dengue immune human sera were obtained by collecting blood samples from 
volunteers who might have been infected during foreign travel.  Of 35 subjects enrolled in 
the study, 17 had antibodies that neutralized one or more DENV serotypes.  The 
neutralization patterns of the 17 immune subjects were consistent with past exposures to 
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DENV1 only (one subject), DENV2 only (four subjects), DENV3 only (four subjects) and 
secondary DENV infections (eight subjects).  These sera were also tested for DENV 
neutralizing antibody by the Centers for Disease Control (CDC) in Fort Collins, CO and the 
Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases 
(NIAID), Bethesda, Maryland.  The CDC and NIAID laboratories reached the same 
conclusions as we did about the past infection history of these subjects (unpublished data 
from Drs Robert Lanciotti, CDC and Steve Whitehead, NIH).  For the current study we 
selected 6 sera representing 2 subjects each who had recovered from primary DENV2, 
primary DENV3 and secondary DENV infections.  The DENV neutralization titers and the 
most likely year and place of infection of these subjects are listed in Table 5.1. 
 
DENV Binding Antibodies in Human Immune Sera 
Experiments were performed to measure the binding properties of antibodies in the 6 
selected immune sera to purified DENV2 and 3.  The immune sera were tested at four fold 
dilutions starting at 1:50.  Antibodies in human DENV immune sera cross reacted with both 
serotypes indicating that the dominant antibodies after primary and secondary infection are 
serotype cross-reactive (Figure 5.1).  End point virus binding titers were calculated for the 6 
sera (Table 5.2).  As expected, subjects with secondary infections had higher titers than 
subjects with primary infections (Table 5.2).  These results indicate that an ELISA with 
whole virus as antigen mainly detects serotype cross reactive antibodies and the assay is not 
predictive of the neutralization properties of the serum sample or past infections history of 
the subject.   
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The DENV particle is made up of envelope (E), membrane (M) and capsid (C) 
proteins.  As E protein is the main target of neutralizing antibody, experiments were done to 
compare the antibody response to E protein and whole virions.  As full length E protein alone 
is not secreted out of cells, we expressed the soluble ectodomain of E (Es) from DENV3 to 
be used as an antigen.  We used immune serum samples # 03 and 11 from primary DENV3 
cases and # 09 and 24 from secondary cases and compared binding to DENV3 and Es from 
DENV3.  Antibodies in human immune sera bound well to both Es and virus particles, but 
greater binding was observed with virus particles compared to Es (Figure 2).  These results 
demonstrate that although the ectodomain of E is a dominant target of antibody, virions 
contain epitopes that are absent in recombinant Es.   
 
Purification and Characterization of Recombinant DENV Envelope Protein Domain III 
(rEDIII) 
Studies with mouse mAbs have demonstrated that most DENV serotype-specific 
antibodies bind to EDIII [11-16]. When using whole virus antigen in an ELISA, the cross-
reactive antibodies in human immune sera are likely to dominate and mask signal originating 
from serotype-specific antibodies.  To develop an assay for measuring serotype-specific 
antibody, recombinant EDIII was expressed as a MBP fusion protein in E. coli (Figure 3).  
Previous studied have demonstrated that EDIII expressed alone or as a MBP fusion protein is 
folded correctly and displays antibody epitopes present on the virion [28-31].  To confirm 
that recombinant DENV2 and 3 MBP-EDIII fusion proteins produced in our laboratory were 
correctly folded, binding assays were performed with eight mouse mAbs that bind to EDIII 
of DENV2 and/or 3.  mAbs 3H5-1, 9F16 and 2Q1899 are antibodies that bind to serotype-
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specific epitopes on the lateral ridge of DENV2 [12,16,32].  As predicted, all three antibodies 
bound to MBP-EDIII from DENV2 but not DENV3 (Table 3).  We used mouse mAbs 8A1, 
14A4 and 1H9 which are serotype-specific neutralizing antibodies that bind to EDIII from 
DENV3 only [27] (unpublished data, Putnak, Wahala and de Silva).  mAb 8A1 and 1H9 bind 
to the lateral ridge of EDIII from DENV3, whereas the 14A4 epitope on DENV3 EDIII has 
not been mapped yet.  mAbs 8A1, 14A4 and 1H9 bound to MBP-EDIII from DENV3 but not 
DENV2 (Table 3).  We also used two neutralizing mAbs that bind to a serotype cross 
reactive epitopes in EDIII and these two antibodies bound to both recombinant proteins 
(Table 5.3). Thus, the type specific and cross reactive neutralizing epitopes on EDIII of 
DENV are preserved in the recombinant proteins used in the current study. 
 
EDIII-reactive antibodies in human DENV immune sera 
After confirming that the recombinant EDIII–MBP fusion proteins expressed 
appropriate serotype-specific and cross-reactive epitopes, the antigens were used to detect 
EDIII-reactive antibody in our panel of human DENV immune sera.  Each immune serum 
was tested in four- fold dilutions starting at 1:12.5.  At high concentrations of serum, 
antibodies in the two subjects with evidence of past primary DENV2 infections bound to 
EDIII from DENV2 better than EDIII from DENV3 (Figure 5.4A and B).  Similarly, 
antibodies in the two subjects with serotype-specific neutralizing antibody to DENV3 bound 
to EDIII from DENV3 better than EDIII from DENV2 (Figure 5.4C and D).  The two 
subjects with evidence of past secondary DENV infections had antibodies that bound equally 
well to both antigens (Figure 5.4E and F).  These results demonstrate that EDIII-reactive 
antibodies that developed after primary infection were specific to the serotype responsible for 
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infection.  The EDIII end-point binding titers also displayed serotype-specificity after 
primary infection (Table 5.2).  In the case of secondary serum samples, the EDIII end point 
titers were similar for both antigens (Table 5.2).  
We compared the amount of antibody in immune sera directed to the whole virus 
versus EDIII.  To measure relative amounts of available EDIII epitopes on viral and 
recombinant protein antigens used in the binding assays, end-point titers were calculated 
using mAbs 8A5 and 12C1 (Table 5.3), which bind to a conserved DENV complex epitope 
on EDIII.  The endpoint titers were 5-10 times higher for recombinant EDIII compared to 
virus (Table 5.2).  This result was expected because the DENV complex epitope on EDIII 
has been mapped to the A-B loop, which is poorly exposed on the intact virus but not on 
recombinant EDIII [16].  Despite the superior binding of 8A5 and 12C1 to recombinant 
EDIII, human immune sera bound poorly to recombinant EDIII compared to the virus 
antigen (Table 5.2).  After primary infections the serotype-specific EDIII-reactive antibodies 
ranged from 0.1 to 8.1% of total virus-reactive antibodies (Table 5.2).  Following secondary 
infections the EDIII-reactive antibodies accounted for 0.2 to 4.0 % of total virus-reactive 
antibodies.  These results indicate that subjects who have recovered from DENV infections 
have low levels of EDIII-reactive antibody and, in the case of primary infections; antibodies 
are directed to serotype-specific epitope(s) on EDIII.   
 
Role of EDIII-reactive Antibodies in DENV Neutralization 
 Experiments were performed to determine the contribution of EDIII-reactive 
antibodies in human immune sera to DENV neutralization. The immune sera were depleted 
of EDII- binding antibodies by incubating the serum samples with MBP-EDIII bound to an 
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amylose resin. The primary DENV2 and DENV3 immune sera were incubated with MBP-
EDIII from DENV2 or DENV3, respectively.  The secondary sera were treated with MBP-
EDIII from DENV2 (Sample 009) or DENV3 (Sample 024).  As depicted in Figure 5.5, 
incubation with recombinant MBP-EDIII removed most of the EDIII-reactive antibody.  The 
treatment specifically removed EDIII-reactive antibodies as sera treated with MBP alone 
were indistinguishable from untreated immune sera (Figure 5.5).  Interestingly, when the 
secondary sera were depleted using MBP-EDIII from one serotype, most EDIII reactivity to 
the second serotype was also lost (data not shown) indicating that in secondary immune sera 
the antibodies are mainly directed against a cross-reactive epitope on EDIII.   
As the recombinant EDIII used in above studies was expressed as a MBP fusion 
protein, it was conceivable that some human antibody epitopes in EDIII were altered or 
masked by the fusion partner.  To determine if MBP fusion partner altered important epitopes 
on EDIII, binding assays were performed with purified DENV2 EDIII without MBP (kindly 
provided by Dr. Michael Diamond, Washington University, St. Louis).  Dengue immune sera 
absorbed with recombinant DENV2 EDIIII-MBP were tested for the presence of antibodies 
that bound to EDIII without MBP.  As depicted in Figure 5.6, immune sera absorbed with 
DENV2 MBP-EDIII protein failed to bind recombinant DENV2 EDIII without MBP 
indicating that the MBP fusion partner does not alter or mask the main human antibody 
epitopes on EDIII.  
Next, untreated and EDIII antibody-depleted sera were tested in the flow cytometry- 
based DENV neutralization assay with U937 cells expressing DC-SIGN.  Figure 5.7 depicts 
neutralization curves for primary DENV2, primary DENV3 and secondary DENV immune 
sera.  Serum samples with or without EDIII-reactive antibodies showed similar neutralization 
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patterns (Figure 5.7).  The 50% neutralization titers were ~ 10-15% lower for serum samples 
depleted with EDIII compared to the MBP treated sera (Table 5.4). These results indicate that 
EDIII-reactive antibodies make a minor contribution to the total neutralizing capacity of 
human DENV immune sera (Table 5.4). 
As it was conceivable that EDIII antibodies might play an important role in DENV 
neutralization in some cell types but not others, some of the experiments with U937 cells 
expressing DC-SIGN (Table 5.4) were repeated with Vero cells.  We selected EDIII 
antibody-depleted serum sample # 03 (primary DENV3 immune) and # 09 (secondary DENV 
immune) and performed neutralization assays with Vero cells.  In the case of sample #03, the 
neutralization titers for DENV3 were similar for untreated and EDIII antibody-depleted 
serum (50% neutralization titers of 74 and 88 respectively).  Similarly, for sample #09, the 
neutralization titers for DENV2 were similar (50% neutralization titers of 895 and 858 
respectively) for untreated and EDIII antibody-depleted sera.  These results demonstrate that 
EDIII reactive antibodies were not required to neutralize DENV infection of U937 cells and 
Vero cells. 
 
5.5 Discussion 
Despite many publications on interactions between DENV and antibody, surprisingly 
few studies have been published on how the binding properties of human antibodies relate to 
DENV neutralization.  The goal of the current study was to characterize the specificity and 
functionality of antibodies in DENV immune human sera.  Here we have demonstrated that 
EDIII- reactive antibodies are present in human immune sera.  The EDIII antibodies mainly 
recognized a type-specific epitopes after primary infection and a cross-reactive epitope after 
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secondary infection.  EDIII-binding antibodies were a minor component of the total 
antibodies in immune sera binding to DENV.  Recently Crill and co-workers used DENV2 
virus-like particles to measure epitopes specific human antibody responses and they also 
observed low levels of EDIII-binding antibodies in human sera [24].  Our results demonstrate 
that EDIII binding antibodies make only a minor contribution to the total neutralizing 
capacity of human immune sera.  Thus, the EDIII neutralizing epitopes that have been the 
focus of much recent work [12,16,17] were not the target of most neutralizing antibody in 
primary and secondary DENV immune sera. 
Several investigators have reported the presence of EDIII-reactive antibodies 
following natural infection of people and animals with flaviviruses [18,20-23].  In human 
WNV-immune sera, EDIII-reactive antibodies were present, although at low levels compared 
to the total antibody binding to virus [19].  Furthermore, investigators have shown that 
EDIII-reactive antibodies are specific for the infecting virus, unlike antibodies against the 
whole virus particle, which are highly cross-reactive [18,20-23].  Our data reported here 
indicate that DENV cross-reactive antibodies dominate in whole virus binding assays.  Our 
data demonstrate that in subjects who have recovered from primary DENV infection, EDIII-
reactive antibodies were mainly directed to an epitope specific for the serotype responsible 
for infection, whereas in secondary cases EDIII-reactive antibodies bound to a DENV cross-
reactive epitope.  Recent studies with mouse mAbs have mapped the location of both cross 
reactive and serotype-specific epitopes on DENV EDIII [12,16,17].  Although it is 
reasonable to speculate that the cross-reactive and serotype-specific epitopes defined by 
mouse mAbs are also targets of the human antibody response measured here, further studies 
are needed to confirm this.   
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Currently, the primary serological assay to identify the DENV serotype responsible 
for a primary infection is the neutralization test, which is a laborious and time consuming 
assay.  Our results indicate that a simple ELISA with recombinant EDIII as antigen can be 
used to identify the DENV serotype responsible for primary infection.  Our results also 
demonstrate that the specificity of EDIII-reactive antibodies is preserved in both early 
(within first year, data not shown) and late (>4 years after infection) convalescent primary 
sera.  In secondary infections, this assay is unlikely to predict responsible serotypes as the 
response is directed to cross-reactive epitope(s) on EDIII.  Ludolfs and colleagues also 
reported similar results using recombinant EDIII in an immunoblot assay with human 
immune sera [23].  Further studies are needed to evaluate the utility of recombinant EDIII as 
an antigen for identifying DENVs responsible for primary infection.  In the case of secondary 
infections, studies need to address if the EDIII-reactive antibodies simply cross-react with the 
serotypes responsible for the primary and secondary infections or if they also cross- react 
with serotypes not responsible for infection.  
Studies with mouse mAbs have led to the identification and mapping of a serotype- 
specific epitope on the lateral ridge of EDIII of several flaviviruses including DENV 
[1,12,16,33].  An implicit, but untested assumption has been that antibodies directed to this 
epitope must play a role in serotype-specific neutralization following natural human 
infection.  Our results demonstrate that DENV-specific EDIII-reactive antibodies play a 
minor role in neutralization observed with human sera.  Studies with immune sera from 
people and horses naturally infected with WNV have also revealed a variable role for EDIII-
reactive antibodies in viral neutralization [18,19].  In some cases, EDIII-reactive antibody 
depletion led to a decrease in WNV neutralization whereas in other cases no significant 
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change was observed [18,19].  Our results do not rule out the possibility of inter-domain 
epitopes involving EDIII making important contributions to neutralization as these epitopes 
would not be present in the recombinant EDIII proteins used in the current study.  We 
conclude that antibodies directed to inter-domain epitopes, epitopes on EDI or II of E protein 
and, possibly M protein, are mainly responsible for the neutralizing activity of human 
immune sera.  
One potential concern is that the recombinant EDIII MBP fusion proteins used here 
may be improperly folded and not display important epitopes present on EDIII in the virus 
particle.  Our studies indicated that the recombinant proteins were correctly folded.  Eight 
EDIII-reactive, neutralizing mouse mAbs bound with appropriate specificity to the 
recombinant EDIII from DENV2 or 3 used here indicating that the main type-specific and 
cross-reactive neutralizing epitopes described in the literature were present on our 
recombinant EDIII proteins [12,16,17,27,32].  Other groups have performed structure studies 
with EDIII expressed alone or as a MBP-fusion protein and demonstrated that the E. coli- 
expressed protein has a structure similar to EDIII in its native form [28-30].  We also 
demonstrated here fusing EDIII to MBP did not mask or alter the main human antibody 
epitopes in EDIII because human sera absorbed with MBP-EDIII failed to bind to EDIII 
without the MBP fusion portion as well. 
In summary, our results indicate that EDIII-reactive antibodies are of minor 
importance in neutralizing DENV by human DENV immune sera.  We propose that the 
major cross-reactive and serotype-specific neutralizing epitopes targeted by human immune 
sera are inter-domain epitopes [34] and/or located outside EDIII.  Currently live attenuated 
DENV vaccines are being tested in human clinical trials [35].  It is reasonable to assume that 
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the protective antibodies induced by these vaccines will be similar to protective antibodies 
induced after a natural DENV infection.  We predict that the quality and quantity of 
antibodies against EDIII will not determine the efficacy of live attenuated DENV vaccines.  
As an alternative approach to live attenuated vaccines, several groups have focused on 
developing recombinant EDIII vaccines [36-38].  Given the low levels of EDIII-reactive 
antibodies detected here in human immune sera, caution is urged in proceeding with EDIII- 
based platforms.  We currently do not understand why people develop low levels of EDIII-
reactive antibody after natural infection.  The human immune system may recognize and 
react to epitopes on EDI and EDII better than to EDIII.  However, with appropriate adjuvants 
and recombinant protein constructs, it might be possible to stimulate an effective immune 
response directed to relevant epitopes on EDIII as well.  Such vaccines are likely to 
neutralize DENV by a mechanism that is different from neutralization observed after natural 
infection.   The topic of flavivirus-antibody interactions has been dominated by studies to 
identify and characterize epitopes on EDIII.  We hope the results reported here will stimulate 
more work to characterize epitopes on EDI and EDII and their role in DENV neutralization. 
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            Figure 5.1: Binding of human immune sera to purified DENV2 and 3.  The 
binding of antibodies in convalescent sera from  patients who  have recovered 
from primary DENV2 infections (A, B), primary DENV3 infections (C, D) and 
secondary DENV infections (E, F) to purified DENV2 (solid lines) or DENV3 
(dashed line) was analyzed by ELISA.  The data points represent mean values and 
the error bars represent the standard error of the mean.  The data shows one of two 
representative experiments.   
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Figure 5.2: Binding of human immune sera to purified DENV3 and the ectodomain 
of E protein.  To compare antibody binding to whole virions and E protein, ELISA plates 
were coated with purified DENV3 or the ectodomain of E protein (Es) from DENV3.  As 
a negative control, plates were coated with chloramphenicol acetyl transferase (CAT) 
protein.  Sera from   patients who have recovered from primary DENV3 infections (03 
and 011) and secondary DENV infections (09, and 024) were used to measure virus and E 
protein specific antibody responses.   
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Figure 5.3: Purification and characterization of recombinant MBP-EDIII fusion 
proteins from DENV2 and 3.  The recombinant protein expressed in E. coli and purified 
by amylase affinity chromatography.  Lanes 1 and 3 depict the DENV2 and DENV3 
MBP-EDIII fusion proteins in E. coli lysates.  Lanes 2 and 4 depict the purified protein 
obtained after amylase affinity chromatography.  The arrow indicated the band 
corresponding to the 53kD MBP-EDIII fusion protein.   
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Figure 5.4:  Binding of human immune sera to MBP-EDIII from DENV2 or 3.  
Convalescent sera from 2 people each who had recovered from primary DENV2 (A, B), 
primary DENV3 (C, D) and secondary DENV (E, F) infections were tested for binding to 
recombinant MBP-EDIII from DENV2 (solid lines) or DENV3 (dashed line).  The data 
points represent the mean values and the error bars represent the standard error of the 
mean.  The data are from one of two representative experiments. 
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Figure 5.5:  Depletion of EDIII-reactive antibody from human immune sera.  
Immune sera were from subjects who had have recovered from primary DENV2 (Panel 
A), primary DENV3 (Panel B) or secondary DENV (Panel C) infections.  The sera were 
absorbed using MBP alone or recombinant MBP-EDIII-fusion protein from DENV2 (sera 
# 01, 09 and 13) or DENV3 (sera #03, 11 and 24).   
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Figure 5.6:  Binding of EDIII antibody depleted dengue immune sera to DENV2 
EDIII without a MBP fusion partner. Dengue immune sera (# 13, and #24) were 
absorbed using DENV2 MBP-EDIII or MBP alone.  The absorbed sera were tested for 
binding to DENV2 EDIII expressed without a MBP fusion partner.  The MBP-EDIII 
absorbed sera failed to bind to EDIII alone indicating that EDIII with or without a MBP 
expressed similar antibody epitopes.  
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Figure 5.7:  DENV neutralization by human immune sera depleted of EDIII binding 
antibodies. Convalescent sera from 2 people each who had have recovered from primary 
DENV2 (A, B), primary DENV3 (C, D) and secondary DENV (E, F) infections were 
depleted of EDIII binding antibody and tested for DENV neutralization at different 
dilutions.  Neutralizing antibody was measured using U937 cells expressing DC-SIGN 
and flow cytometry. Neutralization curves are depicted for untreated (open circles), MBP 
treated (open triangles) and EDIII antibody depleted (dark squares) sera.  The data are 
from one of two representative experiments. 
  
 
 
CHAPTER 6. 
Discussion 
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The data presented in this thesis can be broadly categorized into two major areas; 
understanding the evolution of DENV in Sri Lanka, and understanding the mechanism of 
DENV neutralization by EDIII-reactive antibodies and its relevance to natural DENV 
infection in people.  Therefore, the importance of these findings and the possible future 
directions are discussed in this chapter under these two categories. 
 
6.1. Clade replacement of DENV3 in Sri Lanka and possible role in pathogenesis. 
We studied the evolution and phylogeny of DENVs in Sri Lanka isolated over the 
past three decades.  DENV2 and DENV3 were identified as the predominant DENVs 
circulating in Sri Lanka during this period.  The most interesting change observed was linked 
to DENV3.  It is well established that pre-989 viruses of DENV3 have been replaced by post- 
1989 viruses when DHF emerged in Sri Lanka in 1989 [1].  However, the present study 
further revealed that DF/DHF epidemics after 2000 coincide with the emergence of another 
new clade of DENV3 designated post-2000 clade.  Further studies are needed to directly 
address if the new clades of DENV3 circulating in Sri Lanka are responsible for the recent 
severe dengue disease epidemics on the Island.  We have noticed that DENV2 also followed 
the same temporal pattern of clade replacement as DENV3.  However, our data are not 
conclusive with respect to DENV2 due to weak bootstrap values and the small number of 
virus isolates used.  Therefore, more comprehensive studies are needed on the phylogeny of 
DENV2 in Sri Lanka as well.     
Analysis of the whole genome of different DENV3 in a recent epidemic in Indonesia 
indicated that adaptive selection had a minimal role in the microevolution of DENV3 [2].  In 
this study, the reappearance of an older strain of DENV3 was responsible for the epidemic.  
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Similarly, the emergence of large epidemics in Sri Lanka after 2000 coincided with the 
appearance of a new clade of DENV3 that was closely related to a single Sri Lankan isolate 
from 1993.  (chapter 2, figure 2.5) [1].  Starting in 2000, DENV began to spread to new areas 
in Sri Lanka.  This might also have contributed to a steep increase in the number of cases by 
infecting susceptible people who had not previously been exposed to DENV (Chapter 2- 
figure 2.1) [3].  Most dengue infections in humans are asymptomatic, and silent infections of 
DENV during interepidemic periods have been reported [4-6].  Therefore, further research 
needs to be focused on analyzing the dynamics of silent infections in humans during 
interepidemic periods and tracing the emergence of new lineages of clades of DENV in Sri 
Lanka. 
Contemporary isolates of DENV3 from Sri Lanka infect and disseminate more 
efficiently in mosquitoes than viruses circulating before 1989 [7].  This might suggest that 
new DENV strains on the island are replacing older stains by competitive displacement due 
to their higher fitness in mosquitoes [7,8].  It is known that the extrinsic incubation period 
(EIP; time taken to replicate and disseminate virus in mosquitoes after a blood meal) of 
attenuated DENV is long compared to invasive viruses [9,10].  Therefore, a shorter EIP 
likely provides a mechanism for the selection and transmission of more efficient virus 
strains; especially because a mosquitoes requires more than one blood meal for each 
gonotrophic cycle in its short life span.  Furthermore, an increase in ambient temperature has 
been shown to decrease the EIP in mosquitoes [11].  Apart from that, a subtle change in the 
daily survival rate of mosquitoes in the environment has been proposed to be sufficient to 
turn mild epidemics into massive epidemics of Chikungunya virus, which is transmitted by 
the same Aedes vectors [12].  Therefore, it is important to study these neglected areas of 
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vector biology to understand the mechanisms behind the massive epidemics and phylogenetic 
changes of DENVs in Sri Lanka. 
Investigators have argued that some DENV strains are intrinsically different from 
others by being highly virulent and therefore causing severe DF/DHF epidemics [13-16].  
However, this concept is controversial. DENV genomic sequences isolated from DF patients 
and DHF/DSS patients have been compared, and no detectable, highly reproducible genetic 
differences have been found among them [17].  However, the pitfall of such analysis is the 
assumption that a virus strain can only cause DHF and DSS and not DF or vice versa.  It is 
obvious from the epidemiological data collected in DF/DHF epidemics worldwide that only a 
small percentage of DENV-infected people develop DHF/DSS [18,19].  Furthermore, 
pathogenesis of DHF/DSS is also governed by the interplay among many host factors [19]. 
Therefore it is quite possible that some differences among different virus strains can 
contribute to severe disease along with other host factors. On the other hand, antigenic 
variation among different DENVs has been proposed as an additional factor contributing to 
DHF/DSS.  For example, sera from people immune to DENV1 were able to neutralize the 
American but not the Asian genotypes of DENV2, the latter having been shown to cause 
severe DF/DHF epidemics [20].  This finding was further confirmed in vivo using non- 
human primates as a model of infection [21].   
The only amino acid (AA) difference observed in the viral structural proteins between 
pre-1989 DENV3 and post-1989 DENV3 was located in the E protein at amino acid position 
124 [1].  The amino acid change observed was from Serine to Proline (S124P).  In addition, 
post-2000 serotype 3 viruses contained an additional mutation from Threonine to Alanine at 
position 219 (T219A) in the E protein (figure 6.1a).  Interestingly, AA positions 124 and 219 
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are located in the center of EDII in a hinge region (figure 6.1b).  AA positions at or near 
residue 124 on the E protein of DENV have been identified as part of a mAb binding site by 
neutralizing escape mutant viruses [22].  Furthermore, mouse mAb developed against the 
New Guinea C strain of DENV2 (NGC) did not neutralize SIN/99 strain of DENV2 [23].  
The AA differences found in the E protein between the two DENV2 strains were located at 
AA positions 71, 112 and 124 of the E protein.  Amino acids at positions 71 and 112 are 
proximal to the fusion loop of the E protein whereas the AA at position 124 is located near 
the center of EDII [23].  Since the AA mutations found on the E protein of the post-1989 and 
the post-2000 DENV3 clades were located near the known epitopes of neutralizing 
antibodies, these mutations may alter the binding affinity as well as functional properties of 
neutralizing antibodies.  Furthermore, the mutations may have some effect in the dynamic 
movement of the E protein and thus, may affect the movement of the fusion peptide in the 
acidic environment of the endosome.  Such impacts on the dynamic movement of the E 
protein may also be an important factor in determining the neutralization potential of 
antibodies [24].  In fact, Japanese encephalitis virus (JEV) variants with AA mutations at 
positions 126 and 219 of the E protein demonstrated neutralization differences with a 
neutralizing chimpanzee mAb B3 [25].  The AAs at positions 126 and 219 are located in 
similar positions to residues 124 and 219 of the DENV 3 E protein.  Furthermore, Cummings 
et al proposed that antibody-dependent enhancement (ADE) provides a competitive 
advantage over the non-enhanced viruses especially in a hyperendemic situation [26].  
Therefore, further experiments are needed to test the possible effects of mutations to residues 
124 and 219 on neutralization and ADE by comparing pre-1989, post-1989 and post-2000 
DENV3 strains.  The DENV3 monoclonal antibody panel developed as a part of this study 
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will be an important tool for such experiments.  Furthermore, it will be very important to 
determine how convalescent sera collected from DENV infected patients in Sri Lanka before 
1989 neutralizes and/or enhances (ADE) during infection with  pre- and post-1989 DENV, as 
well as the post-2000 clade of serotype 3 viruses.  In addition, isogenic viruses, which can be 
made by swapping the E gene from different virus clades and genotypes into a common 
DENV backbone of the DENV3 infectious clone, will be a useful platform for answering 
these questions as isogenic viruses can reduce the inherent variability of neutralization 
assays, and will allow specific targeting of individual domains and epitopes.  
The exact role of the mutations at positions 124 and 219 of the E protein of DENV3 
has yet to be determined.  However, some pre-1989 viruses replicated more efficiently than 
post-989 viruses in primary dendritic cells as well as in U937 cells expressing DC-SIGN 
[27].  Interestingly, such differences were not observed in mosquito cells (C6/36) or Vero 
cells. Importantly, adapting a strain of DENV2 to replicate in mice resulted in a mutation at 
position 124 of the E protein, suggesting that this position of the E protein may be a 
determinant of host specificity [28].  According to Prestwood et al., this mutation reduced the 
binding affinity of E protein to heparan sulfate, a putative cellular receptor for DENV; 
increased the half-life of the virus in serum; and increased the systemic viral load leading to 
severe disease in mice [28].  Moreover, mutation at amino acid 122 of E protein of DENV2 
has been involved in modulating mid-gut infection and dissemination of the virus in 
mosquitoes [29].  Therefore it is possible that mutations at positions 124 and 219 of DENV3 
E protein may affect the cellular tropism of these viruses.  Further studies are needed to test 
the role of E protein mutations on the phenotypes of Sri Lankan DENV3 strains. 
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6.2 Neutralization of DENV3 by EDIII reactive antibodies and its role in natural DENV 
infections in human. 
 
Strain variability and differential neutralization of DENV3: 
The data presented in Chapter 4 of this thesis demonstrated that the type-specific 
neutralization epitopes of DENV3 are also located on the lateral ridge of EDIII as shown for 
DENV2 and other flaviviruses such as WNV and JEV.  In addition, bioinformatics analysis 
of 175 E protein sequences representing all the genotypes of DENV3 showed that the E 
protein sequence was not strictly conserved among the different genotypes of DENV3.  The 
variable AA positions of the E protein, referred to as informative sites, were not only 
restricted to EDIII, but also distributed on EDI and EDII as well.  Most of the informative 
sites were located at or near the known epitopes of E protein-reactive, neutralizing Ab 
against the flavivirus.  Our results further demonstrated that the type-specific lateral ridge 
epitope on EDIII was not conserved among the genotypes of DENV3 and consequently the 
binding and the neutralization potential of DENV3 type-specific mAb were affected by 
natural sequence variation located on the lateral ridge epitope of EDIII. 
The long held assumption in the neutralization of DENV is that type-specific 
antibodies neutralize all the strains of a DENV serotype irrespective of the intra-serotype 
genetic variability [16,30].  Our results demonstrated that this assumption is not true, at least 
within the members of DENV3. Due to the fact that EDI- and EDII-reactive Abs cross-react 
and may enhance virus infection rather than neutralizing it, subunit DENV vaccine 
candidates based on EDIII are currently being developed [31,32].  However, our results 
suggest that such vaccines may not elicit EDIII lateral ridge-reactive type-specific antibodies, 
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which neutralize all the strains of a serotype with a similar potential.  Furthermore, such 
vaccine formulations must be concerned with the possibility of enhancement of infection.  
Therefore, EDIII-based vaccines need to be carefully evaluated for their efficacy using all the 
DENV genotypes within a serotype.  On the other hand, 18 informative sites are located on 
EDI and EDII of the DENV3 E protein as well.  The effect of these natural mutations on 
DENV3 neutralization has not been studied.  However, a few studies have already reported 
differential neutralization of DENV3 by DENV immune sera [33-35].  Therefore, further 
studies are needed to address these questions in more detail. 
 
Role of EDIII-reactive antibodies after natural infection in people: 
Neutralization mechanisms of DENV by human immune sera are poorly studied 
mainly due to the polyclonal nature of the Abs present in these sera.  However, it has been 
assumed that EDIII-reactive antibodies make up the dominant proportion of antibodies 
responsible for type-specific neutralization in humans after a natural DENV infection, mainly 
because EDIII-reactive mouse mAbs have been shown to strongly and type-specifically 
neutralize DENV.  The data presented in chapter 5 of this thesis demonstrated that EDIII- 
reactive Abs do not make up the dominant proportion of the DENV-reactive antibodies in 
polyclonal immune sera.  Our results further demonstrate that contribution of EDIII-reactive 
Abs to type specific neutralization in human immune sera is negligible.  Furthermore, non- 
neutralizing type-specific antibodies and non-neutralizing cross-reactive antibodies against 
EDIII are present at  a low percentage compared to total DENV-reactive antibodies present in 
immune sera after primary and secondary infections, respectively (chapter 5, tables 5.2 and 
5.4, figure 5.4 ).  Although, the number of serum samples used in our study was small, the 
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overall results suggested that type-specific neutralization in human immune sera may be 
driven primarily by EDI/EDII-reactive antibodies. 
The work conducted in this thesis lead to the development of several additional 
interesting and challenging research questions, which have not been fully addressed by our 
results.  One important research area is to understand why EDIII reactive neutralizing 
antibodies are not developed after natural DENV infection in humans, and how EDIII based 
vaccine candidates could be improved to elicit EDIII reactive neutralizing antibodies in 
humans.  Another question is whether non-neutralizing, EDIII-reactive antibodies modulate 
ADE.  Furthermore, identifying the major epitopes on EDI/EDII that are potentially 
responsible for type specific neutralization after a natural infection in humans is an ongoing 
and challenging research question, since most of the EDI/II reactive Abs are believed to be 
weakly neutralizing and/or enhancing.  
Although the contribution of EDIII-reactive antibodies in immune human sera to 
type-specific neutralization is negligible, identifying binding sites (or epitopes) of the EDIII- 
reactive antibodies will be an essential component of improving EDIII vaccine candidates.  
Non-neutralizing epitopes on viral proteins can dominate the immune response by out-
competing the neutralizing epitope, leading to an attenuated neutralizing Ab response 
[36,37].  In addition, deletion of non-neutralizing epitope on gp41 of HIV has induced a 
strong Ab response against a neutralizing epitope [36].  Replacing a key residue or few 
residues on the epitopes has also been used to reduce the immunogenicity of epitopes 
[38,39].  
A recent study conducted by Webb and colleagues indicated that mice vaccinated 
with Venezuelan equine encephalitis (VEE) replicon particles which express rEDIII,  did not 
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elicit neutralizing Abs although EDIII reactive non-neutralizing Abs were detected [40]. 
Furthermore, it is known that the immunogenicity of rEDIII depends on adjuvant used in the 
immunization protocol, and some adjuvants did not sufficiently induce the EDIII reactive 
neutralizing Abs. Considering the published literature and the data presented in this thesis, 
we hypothesize that weak immunogenicity of EDIII lateral ridge epitopes in humans may be 
partly due to suppression from highly immunogenic non-neutralizing epitopes on other 
regions of E protein.  Epitopes on EDI, EDII and even epitopes on EDIII outside the lateral 
ridge may suppress the immunogenicity of the EDIII lateral ridge.     
Some exploratory studies were performed to identify the epitops on EDIII bound by 
human antibody.  Studies conducted with the array of mutant EDIII proteins, which have 
been used in chapter 4 of this thesis, and immune sera from people exposed to secondary 
DENV infections demonstrated that more than 50% of the binding was lost when AA 
positions at 304, 308, ( located on A sheet)  326, 328 and 330  (located on BC loop)  were 
mutated on DENV3 EDIII (figure 6.2).  These preliminary data suggest that secondary 
DENV immune sera bind to an epitope that is similar to an epitope centered on the A sheet of 
EDIII, which is recognized by serotype cross-reactive mouse mAbs.  It is also known that 
AB loop of DENV EDIII is highly conserved.  Mutating highly conserved Histidine and 
Threonine residue in the AB loop of EDIII abolished the biding of non-neutralizing mouse 
mAb [41].  Therefore, we speculate that non-neutralizing cross-reactive EDIII antibodies, 
especially in secondary human sera, may bind to the AB loop as well.  However, further 
studies are necessary to identify these epitopes.  
Immunogenicity of an antigen can  be improved by optimizing helper T cell (HTL) 
function by using an universal synthetic peptide or pathogen-derived, broadly cross-reactive 
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HTL epitopes [42-44].  Such binding sites have been used to improve the immunogenicity of 
neutralizing epitopes on viral proteins [37,45].  For instance, synthetic Pan DR helper T cell 
epitopes (PADRE), universal synthetic T helper cell epitope, has been placed next to the 
epitope of the recombinant viral protein of porcine reproductive and respiratory syndrome 
virus (PRRSV) to induce the immunogenicity [37,42].   
Thus, different approaches such as abolishing non-neutralizing epitopes and 
introducing T helper cell epitopes have been used to improve the immunogenicity of 
neutralizing epitopes on proteins from many different pathogens including viruses.  
Improving immunogenicity to the lateral ridge epitope on EDIII may be accomplished using 
any of these approaches or combining them. As anticipated, if the non-neutralizing epitopes 
are identified, those epitope can be mutated to dampen the immunogenicity against them and 
will probably increase the immunogenicity of the lateral ridge epitope which elicits strongly 
neutralizing Abs. On the other hand, universal T helper epitopes such as the PADRE epitope 
may also be a candidate to increase the immunogenicity of the lateral ridge epitope.  PADRE 
has also been placed between non-neutralizing and neutralizing epitopes of recombinant viral 
proteins to induce  immunogenicity of the neutralizing epitope [37].  Therefore, the PADRE 
sequence may be placed proximal to residues at AA position at 300, which is located at the 
center of these lateral ridge epitope on the N-linker region of the EDIII, and this will likely 
exert on a minimal effect on the structure of EDIII. [46,47].  Thus, we anticipate that 
disrupting non-neutralizing epitopes by introducing mutation in those, and inserting PADRE 
or similar T helper cell epitopes close to the center of the lateral ridge epitope, may increase 
the immunogenicity of the lateral ridge epitope and induce a strongly neutralizing Ab 
response in humans. 
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It has been well accepted that EDIII-reactive antibodies are strongly neutralizing 
antibodies and EDI/EDII antibodies are broadly cross-neutralizing and enhancing antibodies 
[22].  However, such conclusions are made based on the data obtained from studies with 
mouse mAbs, assuming that natural human infection with DENV elicits a similar immune 
response to the mouse.  In contrast, the present study suggests that this assumption is not 
correct, and the contribution of EDIII reactive antibodies in human immune sera in the face 
of neutralization of DENV is negligible.  Therefore, it is important to study ADE with regard 
to non-neutralizing EDIII-reactive antibodies in immune sera as the other possible role of 
EDIII reactive antibodies.  Such studies can be pursued either in an in vitro cell culture 
model or an in vivo mouse model by comparing EDIII-reactive antibodies depleted sera to 
un-depleted sera [48].   
According to a recent study, human polyclonal sera collected from DENV infected 
people mainly consist of cross reactive antibodies against highly conserved fusion peptide  
[49].  Furthermore, EDIII-reactive antibodies in WNV-infected individuals are also very rare 
and the strongly neutralizing human monoclonal antibody recovered from such an individual 
binds to EDII and not to EDIII [50-52].  These findings along with the data presented in the 
present study clearly indicate that individuals who have recovered from natural flavivirus 
infection mainly developed antibodies against the EDI/EDII portion of the E protein and not 
to EDIII.  Therefore, it is important to map the antibody epitopes responsible for type- 
specific neutralization after natural human infection.   
Developing human monoclonal antibodies from DENV-infected people is one way to 
characterize the antibody response against DENV in humans.  Although human mAbs 
against DENV will identify interesting epitopes, these mAbs may not represent the total 
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antibody repertoire against DENV in humans.  Thus, human mAb studies should be done in 
parallel with studies to characterize the polyclonal human response.  However, such analysis 
is challenging due to the nature of polyclonal serum.  Nevertheless, our preliminary ELISA 
data with mutant EDIII protein and polyclonal sera have indicated that mutational analysis 
with polyclonal sera can be used to map epitopes of Abs in human sera. Apart from our 
preliminary data, recent work conducted by Li et al indicated that neutralization specificities 
can be analyzed and mapped using polyclonal sera [53].   
Although many studies focused on EDIII, neutralizing mouse mAbs have also been 
mapped on EDI/EDII of the flavivirus E protein (chapter 4, table 4.1).  The flaviviruses share 
a similar E protein structure and most of the informative sites on EDI/II of DENV3, which 
are described in chapter 4 of this thesis, are also located on or near the known epitopes of the 
mouse mAbs generated against the flaviviruses (chapter 4 figure 4.2).  Therefore, these 
informative sites can also be considered as putative human polyclonal antibody binding sites. 
This assumption is further corroborated by a recent work conducted by Vogt et al [51].  A 
strongly neutralizing human mAb against WNV was mapped to EDI/II hinge region which 
had already been mapped by mouse mAb [22,51].  In addition, conformational epitopes on 
the E protein dimer can be predicted by using a computer algorithm such as CEP 
(Conformational Epitope Prediction server; Bioinformatics Centre, University of Pune, Pune 
411 007. India).   A program such as CEP can also be used to predict an inter-monomeric 
epitope, which is located between the two adjacent subunits of the E dimer.  Inter-monomeric 
epitopes have been reported for flaviviruses and influenza virus [54,55].  Combining the 
information from informative sites, mouse and recent Chimpanzee mAb epitopes, and 
epitopes predicted using CEP; amino acids on EDI/II can be predicted and selected as 
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putative antibody binding sites.  Such AA can be mutated individually or in groups using the 
recombinant DENV3 infectious clone to generate mutant viruses which would subsequently 
be used in neutralization assays with human polyclonal sera.  In addition it might be possible 
to make chimeric viruses comprising EDI/EDII from one serotype and EDIII from another 
serotype of DENV [56].  Using recombinant E protein in these approaches may not be 
successful since strongly neutralizing EDI/EDII-reactive human monoclonal antibodies 
against flavivirus only recognized the whole virus particles and not the recombinant E 
protein [51,52].  Depleting antibodies in primary human polyclonal sera with a heterologous 
purified whole DENV can also be used to remove cross-reactive antibodies, and such 
depleted sera will be a very useful tool in identifying serotype specific EDI/EDII antibodies 
and their epitopes, as well.   
 
rEDIII as a diagnostic tool to detect DENV infection and to discriminate primary infection 
from secondary infection:  
The data presented in chapter 5 indicate that primary immune sera recognize only one 
rEDIII protein representing the infected DENV serotype, whereas secondary immune sera 
cross-react with rEDIII from all DENV serotypes.  Therefore, our data suggest that rEDIII 
can also be used as a diagnostic tool. Although, EDIII has already been described as a choice 
of antigen for detecting flaviviruses, our study further suggests its use as an ideal antigen to 
detect the infected serotype and to discriminate primary infection from secondary DENV 
infection.  However, further studies are needed to confirm our finding using a larger panel of 
sera. Furthermore, in our experiments we observed low level cross reactivity in primary 
DENV immune sera among the EDIII from different DENV serotypes, although this cross 
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reactivity did not hamper type-specific detection.  The AB loop of EDIII, which is highly 
conserved among DENVs, contains non-neutralizing cross-reactive Ab binding epitopes [41]. 
Cross-reactive binding can be abolished by mutating Histidine and Threonine residues in the 
AB loop, and these EDIII mutant proteins will be a more specific antigen for the diagnostic 
purposes. 
 Neutralization assay is the only available tool to determine the DENV serotype 
responsible for the past primary infection from convalescent serum samples.  Unfortunately, 
neutralization assays are expensive, time consuming and require technical excellence in 
tissue culture.  Therefore, the neutralization assay is not a feasible technique in larger scale 
seroprevalence studies especially in developing countries where dengue is hyperendemic. 
However, rEDIII ELISA may be used to identify the infecting serotype if it is a primary 
DENV infection.  Furthermore, the rEDIII ELISA has shown a wide range cross reactivity 
between EDIII from all of the DENV3 serotypes in secondary infection.  On the other hand, 
neutralization assays also show a wide range of cross neutralization between DENV 
serotypes and thus the serotype responsible for secondary infection cannot be identified.  
Therefore, an ELISA, based on an improved EDIII protein, will be a better and more cost- 
effective tool to diagnose, to discriminate secondary infection from primary infection, and 
finally to identify the infecting serotype of DENV in a simple, single assay format. 
 
In summary, the present study demonstrated that severe epidemics of DF/DHF in Sri 
Lanka reported after 2000 were due to the emergence of a new clade of DENV3 and possibly 
DENV2.  Furthermore, our study emphasizes the need for more elaborate studies in 
microevolution of DENV in Sri Lanka, especially focusing on neglected research areas.  The 
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major breakthrough of the present study is to confirm that antigenic properties among the 
genotypes of DENV3 serotypes are not conserved, and that the EDIII reactive antibodies are 
not the dominant type-specific neutralizing antibodies after a natural infection in humans.  I 
believe that the data presented here in the current study have contributed to a better 
understanding of humoral immune response after natural DENV infection and will stimulate 
novel research on natural and vaccine-induced immunity to DENVs.  
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Figure 6.1. Amino acid difference of E protein among pre-1989, post-1989 and post- 
2000 DENV3 clinical isolates. A. Sequence alignment of representative isolate from each 
DENV3 clade. Positions 124 and 219 are not conserved. B. Location of amino acid 
mutation on the E protein dimer. EDI, EDII and EDIII are color coded in red, yellow and 
blue respectively. Amino acid 124 and 219 are located EDII.  
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Figure 6.2.  Relative binding of secondary DENV immune sera (serum # 09 and # 
24) to mutant rEDIII.  Amino acid at each position on rEDIII from DENV3 genotype 
II was replaced by Alanine residue. The binding of immune sera to each mutant rEDIII 
was graphed as a relative percentage of binding compared to parental rEDIII of 
genotype II. 
